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ABSTRACT 
 
 
Respiratory syncytial virus (RSV) is one of the leading causes of bronchiolitis in 
children. We have shown that neonatal mice respond to primary RSV infection with T 
helper type 2 (Th2) biased immune responses, which are enhanced following reinfection. 
Dendritic cells (DCs) including myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) 
play important roles in driving host responses to RSV infection. mDCs present antigens 
to help Th cells differentiate, and pDCs protect against viral infection through type I 
interferons (IFNs). Despite data demonstrating importance of mDCs and pDCs in 
protection against RSV, it has not been studied in an age appropriate model.  
 
Using a neonatal mouse model, we have shown that downregulation of IL-4 
receptor alpha (IL-4Rα) on pulmonary myeloid dendritic cells (mDCs) via antisense 
oligonucleotides protected against RSV induced Th2 immunopathology. Thus, we 
examined the role of IL-4Rα on mDCs in RSV infection. Here, we discovered that IL-
4Rα is developmentally regulated such that neonates have higher levels of IL-4Rα on 
mDCs. To determine if this elevated expression of IL-4Rα on mDCs was responsible for 
RSV pathogenesis in neonatal mice, we specifically deleted it from neonatal mDCs (or 
overexpressed it on adult mDCs) and studied RSV pathogenesis using our neonatal 
mouse model of RSV infection. Deletion of IL-4Rα from mDCs in our neonatal RSV 
infection model resulted in reduced disease as evidenced by reduction in Th2 biased 
inflammation and mucus cell hyperplasia and production. This was accompanied by 
improved lung function and enhanced mDC maturation status after infection. 
Furthermore, overexpression of IL-4Rα on adult mDCs was able to induce RSV disease 
similar to that observed in our neonatal model of RSV infection (i.e., Th2 biased 
responses including mucus hyperproduction). In vitro CD4+ T cell differentiation assays 
using mDCs from neonatal littermate control or IL-4Rα-/- mice were also performed to 
determine the specificity of the in vivo response.  
 
Low levels of type I IFNs have been reported in the nasal aspirates of RSV-
infected infants. Since pDCs are responsible for a significant proportion of type I IFN 
production, we characterized the role of type I IFNs and pDC responses in the 
immunopathogenesis during RSV reinfection in our neonatal mouse model. We found 
that neonatal pDCs, while recruited to the airways, are recruited in low numbers in the 
response to neonatal RSV infection. Further, those pDCs that are recruited produce 
insufficient quantities of type I IFNs. Supplying IFN-α or adult pDCs locally to the 
neonatal mouse prior to RSV infection in neonates abrogated RSV induced 
immunopathophysiologies and this protection remained even after reinfection. 
Specifically, it reduced Th2 responses and lung inflammation and improved lung 
function. This improvement was due to a decrease in viral load and IL-4Rα expression on 
Th2 cells after IFN-α treatment.  
 
The severity of RSV pathogenesis in infants stems partly from immature immune 
responses. Our data demonstrate that developmentally regulated IL-4Rα expression on 
mDCs and inefficient type I IFN production from neonatal pDCs are critical for 
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protection against RSV induced immunopathophysiologies. This study highlights critical 
differences between neonatal and adult DCs in RSV infection.  
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CHAPTER 1.    INTRODUCTION 
 
 
Background 
 
 
Respiratory Syncytial Virus 
 
In 1956, a virus infection in chimpanzees at the Walter Reed Army Institute of 
Research induced cold like symptoms and was named coryza agent (1). In 1957, Chanock 
found a similar virus in two human infants with severe respiratory illness, and a few years 
later, many children with respiratory symptoms were diagnosed with the same virus (2). 
This coryza agent induced the formation of multinucleated giant cell syncytia in tissue 
cultures, so it was named respiratory syncytial virus (RSV). RSV is one of the leading 
causes of respiratory infection in infants. It is ubiquitous and infects almost every child 
by age 2, with recurrence and reinfection being quite common (3). Generally, RSV 
causes common cold like symptoms and mild illness. However, in some infants RSV 
infection causes severe bronchiolitis requiring hospitalization. Mortality due to RSV 
infection is also considerably high accounting for as much as 66,000 -199,000 deaths 
with 99% occurring in developing countries (4). Although RSV was discovered over a 
half a century ago (1), we still have not been able to develop a vaccine to protect against 
RSV infection. 
 
 
RSV Virology 
 
RSV is a negative-sense, single-stranded RNA virus; it is enveloped, non-
segmented and belongs to the family paramyxoviridae and subfamily of pneumovirinae. 
The RSV genome is about 15.2 kb long and consists of 10 genes (Figure -1-1). Genes 
named N, P, M, L, and M2 help in the assembly of the virus. The two genes, NS1 and 
NS2, play a role in evading immune responses by interfering with the production of type 
I interferons (IFNs) (5). G and F surface proteins are implicated in viral entry by allowing 
attachment and fusion respectively to the cell’s plasma membrane. These surface proteins 
are of interest because neutralizing antibodies can be raised against them. G protein is 
heavily glycosylated and has variable regions. Based on the variability of G protein and 
reaction against monoclonal antibodies, RSV has been divided into two types RSV A and 
RSV B (6). RSV A is further subdivided into 12 genotypes and RSV B into 20 genotypes 
(7). G and F protein are known to modulate immune responses. A CX3C motif in the G 
protein binds to CX3CR1 receptor on epithelial cells and competes with the CX3CL1 
chemokine for binding. Since CX3CL1 chemokines are chemoattractants for 
inflammatory immune cells, G protein competition with CX3CL1 affects immune cell 
trafficking (8). Unlike G protein, F is highly conserved, so some drugs are targeted 
against this protein (9). 
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Figure 1-1. RSV genome. 
The human RSV genome is approximately 15.2 kb in length and consists of 10 mRNAs 
and 11 proteins. NS1 and NS2 are nonstructural genes that encode NS1 and NS2 proteins. 
N, P, M2, L encode structural proteins. SH, G, and F encode envelope proteins for 
attachment and fusion. M encodes for matrix protein (10, 11). 
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Clinical Signs, Symptoms, and Treatment 
 
RSV is highly contagious and generally infects the upper respiratory tract (URT) 
and causes cold like symptoms such as coughing, sneezing, wheezing, fever, and otitis 
media (4). Unfortunately, it sometimes infects the lower respiratory tract (LRT) and 
causes bronchiolitis and pneumonia (4). Usually, the symptoms last for about 4-8 days; 
and if hospitalized, the length of hospital stay ranges from 3-7 days (10). However, 
preterm babies and immunocompromised patients, who are at the highest risk of 
developing severe bronchiolitis during RSV infection, can be hospitalized for several 
months (11). 
 
Treatments available for infants are supportive care such as hydration and saline 
nasal drops to clear the nasal passage for breathing. Oxygen and mechanical ventilation 
are given to patients with higher risks of respiratory failure, which are often those with 
congenital birth and heart defects (3, 12). Bronchodilators, corticosteroids, and ribavirin 
(antiviral) are expensive and do not provide much benefit in these patients (13). 
Palivizumab, a monoclonal antibody against the F protein of RSV, is used as a 
prophylactic and has been shown to neutralize the virus and abrogate pathogenesis (14, 
15). However, it is expensive (about $1000 for 100mg) and only given to children at high 
risk like preterm babies and children with congenital heart or lung disease. Several 
antivirals and small molecules such as fusion inhibitors and polymerase inhibitors have 
been developed but are still in clinical trials (16, 17). Due to the failure of the formalin 
inactivated RSV vaccine trial of the 1960s, the progress of vaccine development has been 
slow. No approved vaccines are available for RSV. 
 
 
RSV Burden on Health Care System 
 
Every year, RSV infection results in hospitalization for over 3 million children 
and almost 66,000 deaths worldwide (3, 4). In the US alone, 85,000 to 144,000 children 
are hospitalized due to RSV every year (3). Although the mortality rate is higher in 
developing countries, the burden of health care in developed countries is also 
significantly high. An estimated $2.6 billion dollars is spent on medical treatment for 
RSV in the US exerting an enormous burden on the pediatric heath care system. (18). 
RSV accounted for 15% of pediatric office visits and 18% of emergency department 
visits out of 5067 children less than 5 years of age in the 2004 winter season according to 
a study conducted in Nashville, Rochester, and Cincinnati (3). It remains the number one 
etiological agent for hospitalization of infants compared to any other respiratory 
pathogens including influenza (19). 
 
RSV is not only a risk for children but also a problem for adults. 10-20% of 
pneumonia and respiratory problems in nursing homes stems from RSV infection (20). 
Cough, fever, wheezing, and nasal congestion are some common symptoms in elderly 
patients. About 10,000 adults die every year due to RSV infection in the US, and 100,000 
admitted to the hospital for respiratory symptoms (20). RSV can also be life threatening 
for patients who are immune compromised such as HIV patients, transplant recipients, 
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cancer patients receiving chemotherapy, and patients with heart or lung defects such as 
COPD patients (21). 
 
 
RSV Bronchiolitis Risk Factors 
 
Some RSV infected children experience mild illness, while others develop severe 
bronchiolitis. Several factors confer risk for developing bronchiolitis including age, 
prematurity, low birth weight, sex, economic status, the number of siblings, genetic 
factors, etc. (3). Infants less than 6 months of age are more prone to developing 
bronchiolitis upon RSV infection (22, 23). Single nucleotide polymorphisms (SNPs) in 
various genes such as IL-8, IL-4Rα, IL-4, IL-13, TLR-4, IFNA5, surfactant, vitamin D 
receptor have also been determined as risk factors for severe RSV disease (24, 25). Males 
are more susceptible to RSV LRTI and have a higher mortality rate due to RSV infection 
than females (26). Maternal factors such as smoking, unhealthy diet, low vitamin D 
levels, and breast-feeding have all been associated with increased risk to develop RSV 
bronchiolitis (25, 27, 28). 
 
 
RSV and Infant Immunity 
 
Susceptibility of infants and neonates to RSV infection can be attributed to their 
immature lung development as well as immune responses which are different from that of 
adults. Both quantitative and qualitative differences have been discovered in the immune 
response of infants compared to adults (29). Monocyte progenitor cells, granulocytes and 
natural killer T cells (NKT) are significantly lower in number in cord blood from human 
newborns compared to those in adult peripheral blood (29). Phenotypically, human 
leukocyte antigen (MHCII) and CD40 expression are lower on fetal monocytes and 
dendritic cells compared to adult when stimulated with LPS (30). TLR signaling is also 
compromised in the infant with reduced overall TLR expression (31). However, some 
inflammatory cytokines such as IL-6, IL-10, IL-23, and phosphate molecules such as 
cAMP are produced in copious amounts in human cord blood mononuclear cells (32-34) 
suggesting unruly control of inflammation such that the infant immune system is 
considered to be distinct from that of an adult. 
 
Besides innate immune responses, the factors that affect adaptive immune 
responses such as soluble blood plasma concentrations of adenosine and complement 
components are also lower in neonatal cord blood compared to adults (29). Further, 
mounting evidence suggests that the infant immune system is T helper type 2 cells (Th2) 
biased compared to that of adults (35, 36). Naïve CD4+ T cells of neonates and infants 
from cord blood and PBMCs preferentially develop into IL-4 producing CD4+ Th2 cells 
compared to adult naïve CD4+ T cells (37).Similar findings of Th2 bias in neonatal 
animals have been reported as well (38, 39). The reasons for this Th2 biased responses in 
human infants are due to various factors such as low production of T helper 1(Th1) 
promoting cytokine, IL-12 by dendritic cells (40) and increased levels of IL-10 (34). 
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Hypomethylation of the Th2 locus in murine neonatal T cells is another factor that makes 
Th2 genes readily available to transcription factors (41). 
 
Furthermore, RSV infection in infants has been shown to further exacerbate this 
Th2 biased response (42, 43). IL-4 cytokine occurs at higher concentrations than 
interferon  (IFN, a Th1 cytokine) in bronchoalveolar lavage fluid (BAL) of infants 
diagnosed with RSV (42). Moreover, a study comparing Th2 cytokines in serum of RSV 
infected versus influenza infected infants showed higher amounts of Th2 cytokines (IL-4 
and IL-5) in RSV patients (44), suggesting the Th2 biased response is virus specific. In 
fact, researchers studying the immune response after RSV bronchiolitis followed a cohort 
during the first 6 years of life and found that Th2 cytokines in patients with RSV 
bronchiolitis increased over time, and Th1 cytokines decreased after RSV infection (45). 
Further, autopsy results from children that died from severe RSV infection after receiving 
a formalin-inactivated RSV vaccine and being infected with RSV showed increased 
eosinophils (indicative of a Th2 response) (46). Thus, this Th2 bias is thought to 
contribute to RSV pathogenesis. 
 
 
Neonatal Mouse Model: An Age Relevant Model for RSV 
 
Several models for RSV infection have been proposed and studied. RSV infection 
has been studied in primates, sheep, rats and mice. Nonhuman primates like chimpanzees, 
rhesus monkey, bonnet monkey, and baboon are better models to study human RSV but 
cost restrictive, and the use of chimpanzees are restricted by NIH. Cotton rats are more 
permissive to RSV infection compared to ferrets (47) and have also been used in vaccine 
and therapeutic studies for RSV. Cotton rats also show pulmonary histopathology similar 
to humans including peribronchiolitis, perivasculitis, and interstitial pneumonitis (48). 
However, unlike humans, the cotton rat model does not generate pulmonary eosinophilia 
(a characteristic Th2 effector cell). Mouse models are used to study RSV due to their 
short gestation period and availability of reagents. BALB/c mice have been used by a 
number of laboratories to understand RSV pathogenesis, due to the availability of 
transgenic and knockout lines to address mechanistic questions and most importantly 
because they are susceptible to RSV infection and are predisposed to mount Th2 
responses. 
 
Since age at initial infection inversely correlates with RSV severity (49, 50), the 
use of an adult mouse model seemed unjustifiable. Our group (51, 52) and others have 
established a neonatal mouse model of RSV infection (53-56). Neonatal mice are defined 
as 5-7 days of age and are immunologically similar to human infants of 0 to 6 months of-
of age as reviewed in (57). In this model, neonatal mice are infected as neonates with 
RSV. This single infection induced lung dysfunction, mucus hyper-production, and 
airway remodeling compared to the mice infected as weanlings or adults (53). Further, 
reinfection of these mice as adults enhances RSV immunopathophysiology (e.g., 
exaggerated pulmonary Th2 cells/cytokines, eosinophilia, and airway hyperreactivity) 
(Table 1-1) (52, 53). 
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Table 1-1. A comparison of neonatal and adult mouse RSV infection models with 
severe RSV disease in human infants. 
 
Characteristics Severe Human RSV 
Infection (<1year old) 
Neonatal Mouse Model 
(<7days old) 
Adult Mice 
Wheeze    
Mucus   * 
Pulmonary 
eosinophilia 
   
Th2-biased immune 
response 
   
Epithelial sloughing    
Epithelial 
hypertrophy 
   
Hyperplasia of 
goblet cells 
   
Increased 
extracellular matrix 
deposition 
   
Long-term Airway 
hyperresponsiveness 
   
 
Notes: *: means RSV strain dependent 
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Different clinically relevant strains of RSV other than A2 have been used in adult 
mice to elicit disease similar to that observed in severe RSV-infected infants (58, 59). 
However, these are still adult mice with fully matured immune and pulmonary systems 
and it is not clear how relevant this data is to infant airway disease resulting from RSV 
infection. To study the appropriate immunopathologies resulting from priming of 
neonatal immune responses by RSV, our group used a chimeric virus (rA2-19F) in a 
neonatal mouse model (60). This model elicited more severe disease including interstitial 
pneumonitis and alveolitis as observed in some human infants. 
 
 
RSV and Asthma 
 
Numerous studies suggest that there is a link between RSV infection and asthma 
that is not due to atopy or parental asthma (49, 50, 61, 62). While all studies note a long-
term association between RSV bronchiolitis and asthma, the duration of lung dysfunction 
following RSV infection is disputed. For example, while the Tucson study noted an 
association between RSV infection and wheeze, it also noted that this association was lost 
when the children reached 13 years of age (61). Other studies including those of Sigurs et 
al (50) and Piippo-Savolainen et al (62) demonstrated associations between RSV and 
asthma that lasted until adulthood (18-22 years of age). It is interesting to note the 
differences between these studies, in the Tucson study children were 1-3 years old 
(median age > than 1 year old) years old and had mild disease. Whereas, in the later 
studies, children were under 1 year of age (median age < 6 months) and were hospitalized 
(i.e. had severe disease). The Tennessee Asthma Bronchiolitis Study (TABS) 
demonstrates that age during RSV season is an important risk factor for later wheeze 
(49). In total, these studies suggest that age (infants less than a year old) and severity 
(hospitalization) are independent predictors of development of asthma following RSV 
infection. 
 
 
T Helper Type 2 Cells’ Role in RSV Pathogenesis and Asthma 
 
Th2 cells are needed for immunity to extracellular infections such as helminths 
and parasites. RSV infection also activates Th2 cells leading to the production of IL-4, 
IL-5, and IL-13 cytokines. These cytokines promote IgE and IgG1 antibody production 
by B cells against RSV (63). Granulocytes (i.e. eosinophils, basophils, and mast cells) 
have receptors for IgE, and they are attracted to the inflamed tissues by chemokines 
produced from the RSV infected cells (64). Cross-linking of the surface bound antibody 
IgE and IgG1 to its antigen causes these cells to degranulate and release inflammatory 
mediators such as leukotrienes, prostaglandins, and histamines (64). These inflammatory 
factors cause vascular permeability, swelling, and smooth muscle cell contraction. 
Chronic inflammation also leads to remodeling like wall thickening, sub-epithelial 
fibrosis, and smooth muscle hyperplasia (65, 66). Thus, RSV infection in infants 
promotes Th2 cells and Th2 cytokine IL-13 which causes airway remodeling, mucus 
hyperproduction and airway hyper-reactivity similar to allergic asthma. 
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Dendritic Cells – Guide T Cell Differentiation in RSV Infection 
 
Dendritic cells constantly patrol the mucosal surfaces and act to initiate the 
adaptive arm of the immune response in the course of RSV infection. As the viral burden 
increases, different types of dendritic cells are recruited into the lungs at the time of 
infection, conventional dendritic cells or myeloid dendritic cells (mDCs) and 
plasmacytoid dendritic cells (pDCs). mDCs present antigen to T cells, and are divided 
into two subtypes which interact with different T cells. CD11b+ mDCs mainly present 
antigens to CD4+ T cells and thus guide Th cell differentiation (67), while CD103+ mDCs 
mainly cross-present antigens to CD8+ T cells (68). Besides interaction with T cells, DCs 
also produces other pro-inflammatory cytokines such as IL-1β, IL-6, IL-12, IFN-, and 
TNF-α, (69) and chemokines such as CCL2, CCL3, CCL4, CXCL8 (70) to orchestrate 
the immune response. The type of immune response elicited depends on the interaction 
between the mDCs and the naïve T cells, and the cytokine milieu present at the time. 
Mouse studies have shown that neonatal mDCs produce low levels of IL-12 and sub-
optimally stimulate Th cells and cytotoxic Tc cells compared to adult mDCs (71). So we 
believe that low IL-12 levels and sub-optimal stimulation of Th cells lead to their 
differentiation into Th2 cells resulting in a Th2 dominant response in the lungs after RSV 
infection (72, 73). 
 
 
pDCs and Type I Interferons (IFN) 
 
pDCs are a small subset of DCs which initiate an antiviral response by producing 
type I IFNs (74). Several studies have shown a protective role for pDCs and type I IFNs 
in RSV infection in the adult mice (75). However, the role of pDCs and type I IFNs in the 
neonates are unclear. Despite the presence of pDCs in nasal washes from children 
infected with RSV, there are low levels of type I IFNs suggesting a limited response from 
neonatal pDCs (76). Further, type I IFNs have been shown to promote Th1 
differentiation, so we hypothesize that low levels of type I IFNs in infants and neonates 
during RSV infection pushes T helper cell away towards Th2 response (77). 
 
 
IL-4 and IL-13-Distinctive Roles in RSV Disease 
 
Polymorphisms in IL-4 and IL-13 have been linked to severe RSV infection [41]. 
However, these two Th2 cytokines have distinctive roles in Th2 mediated disease. IL-4 is 
mostly responsible for Th cell differentiation and basophil activation, while IL-13 is 
required for mucus hyperproduction and airway hyperreactivity. IL-13 is thought to be a 
primary cytokine that induces lung dysfunction after RSV infection. Patients with severe 
RSV disease during infancy produced higher levels of IL-13 when their sera were tested 
with RSV F and G antigen later at 5 years of age (73). Further antibodies targeting IL-13 
post RSV infection decreased airway hyperreactivity (AHR) and mucus hyperproduction 
after RSV infection in mice (78). 
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Interleukin 4 Receptor Alpha (IL-4Rα) Is Correlated with RSV Pathogenesis 
 
Both IL-4 and IL-13 use a common receptor subunit called IL-4Rα. 
Polymorphisms in IL-4Rα in humans have been associated with RSV hospitalizations and 
disease severity (79). The interleukin 4 receptor (IL-4R) is a heteromeric receptor found 
on a variety of immune cells such as dendritic cells, T cells, and B cells. There are two 
types of IL-4R. Type I consist of the IL-4Rα subunit and the common gamma chain, and 
primarily bind IL-4. The type II receptor consists of the IL-4Rα subunit and the IL-
13Rα1 and binds both IL-4 and IL-13. Signaling for both of these receptors occurs 
through JAK-STAT pathways (Figure 1-2). STAT 6 drives the transcription of GATA 3, 
which promotes Th2 differentiation from the type I IL-4R (80). Downregulation of IL-
4Rα using antisense oligonucleotides (ASO) during RSV infection in neonatal mice has 
been shown to mitigate the Th2 biased response and prevent pulmonary pathophysiology 
(51). A prominent decrease was seen in levels of IL-4Rα on mDCs with the use of ASO 
in mice prior to RSV infection. Thus, we hypothesize that IL-4Rα on mDCs can play a 
significant role in inducing Th2 biased responses in RSV infection of neonates. 
 
 
Summary and Hypothesis 
 
RSV is a respiratory pathogen that infects infants worldwide and is capable of 
eliciting significant airway disease, which can result in long-term lung dysfunction in 
some individuals, and even mortality. RSV severity and the predisposition to develop 
asthma correlates with the initial age of RSV infection. Thus, we have been investigating 
the differences in infant and adult immune responses to RSV infection using neonatal (to 
mimic human infant) and adult mice. Since DCs guide Th2 differentiation which has 
been implicated in RSV pathogenesis, this dissertation sought to study the role of 
neonatal mDCs and pDCs in Th2 differentiation. 
 We previously observed that downregulation of IL-4Rα, which binds Th2 
cytokines IL-4 and IL-13, abrogates RSV induced Th2 pathogenesis. This was 
associated with downregulation of IL-4Rα on pulmonary mDCs. Thus, we 
hypothesized that IL-4Rα on mDCs plays a role in the development of the Th2 
biased response to RSV. (Chapter 2) 
 Further, several studies have suggested a role for pDCs and type I IFNs in 
protection from severe RSV disease. We hypothesized that neonatal pDCs elicit a 
limited type I IFN response allowing for Th2 immunopathophysiology in RSV 
infection. (Chapter 3) 
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Figure 1-2. IL-4R subtypes. 
The type I IL-4R consists of IL-4Rα subunit and common gamma chain(c) and binds IL-
4. The type II IL-4R consists of IL-4Rα subunit and IL-13Rα1 and binds both IL-4 and 
IL-13. These receptors act through the JAK-STAT pathway to activate STAT 6. Type I 
IL-4R is present on T cells, eosinophils, B cells, monocytes, fibroblast, and DCs. Type II 
IL-4R is present on smooth muscle cells, B cells, monocytes, fibroblast, and DCs. (83). 
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CHAPTER 2.    IL-4Rα ON DENDRITIC CELLS IN NEONATES AND TH2 
IMMUNOPATHOLOGY IN RESPIRATORY SYNCYTIAL VIRUS INFECTION* 
 
 
Introduction 
 
Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections 
in infants, and it is the leading cause of bronchiolitis in children under one year of age (3, 
81). RSV infection severe enough to require hospitalization during infancy is associated 
with increased risk for wheezing and development of asthma (50, 82). Currently, no 
effective vaccines or therapeutics for RSV exist. The development of such products is 
partially hindered by our lack of the knowledge of the infant immune system and its 
response to RSV infection. 
 
RSV infection in infants induces a Th2-biased immune response, which is partly 
responsible for RSV pathogenesis (43, 83). A study comparing cytokine levels in the 
serum of RSV vs. influenza infected infants found higher concentrations of Th2 
cytokines (IL-4 and IL-5) in RSV infected children (44), suggesting that the Th2-biased 
response is not simply an age-specific response but also a virus-specific response. Animal 
studies have reported similar findings (38, 52). Age at initial RSV infection is important 
in determining the Th2 bias (53); infection of neonatal mice and reinfection upon 
adulthood induces a Th2-biased immune response (51, 53, 54). Further, polymorphisms 
in IL-4 receptor alpha (IL-4Rα) have been associated with RSV disease severity (79). We 
have previously shown that downregulation of IL-4Rα with antisense oligonucleotide 
(ASO) during primary RSV infection in neonatal mice mitigated the Th2-biased 
immunopathophysiologies upon reinfection (51) which raises the intriguing possibility 
that IL-4Rα plays a role in the immunopathogenesis of neonatal RSV infection. 
 
Dendritic cells are antigen presenting cells that initiate and dictate the ensuing 
adaptive immune response following exposure to a pathogen. Dendritic cells are 
functionally divided into two main classes, myeloid dendritic cells (mDCs) and 
plasmacytoid dendritic cells (pDCs). mDCs present antigens to T cells and help T cell 
differentiation, (84) whereas pDCs produce type I IFNs to combat viral infection (74). 
mDCs are further classified into CD11b+ mDCs that mainly present antigens to CD4+ T 
cells (67, 68) and CD103+ mDCs that mainly cross-present antigens to CD8+ T cells (68). 
Several functional and phenotypical differences have been shown between neonatal and 
adult DCs (29, 71, 85). Additionally, RSV infection induces significantly less recruitment 
of pDCs and thus type I IFNs in the lung of neonatal vs. adult mice, (86) and pDCs from 
cord blood express lower levels of type I IFNs compared to pDCs from adult peripheral 
blood in response to RSV stimulation ex vivo (87). 
 
-------------------------- 
*Adapted with permission. Shrestha B, You D, Saravia J, Siefker DT, Jaligama S, Lee 
GI, Sallam A, Harding JN, Cormier SA. IL -4Rα on dendritic cells in neonates and Th2 
immunopathology in respiratory syncytial virus infection. JLB. 2017. In Press.  
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Neonatal mDCs express lower levels of costimulatory molecules (CD80 and 
CD86) and produce less IL-12 (a Th1 cytokine) in response to LPS compared to their 
adult counterparts (29, 71). 
 
In the present study, we demonstrated an age-dependent expression of IL-4Rα on 
pulmonary DCs. Neonatal CD11b+ mDCs (CD11c+ MHCII+ CD11b+) and pDCs (CD11c+ 
PDCA-1+) expressed higher levels of IL-4Rα compared to their adult counterparts, 
whereas neonatal CD103+ mDCs (CD11c+ MHCII+ CD103+) expressed less IL-4Rα than 
in adults. Since the age at initial infection is important in determining the Th2-biased 
immune response to RSV infection (52, 54, 88) and CD11b+ mDCs are mainly 
responsible for antigen presentation and activation of CD4+ T cells, (67, 68) we 
hypothesized that the elevated expression of IL-4Rα on neonatal mDCs is responsible for 
the Th2-biased immunopathogenesis of neonatal RSV infection. To test this hypothesis, 
we infected mice deficient in IL-4Rα CD11b+ mDCs (89) and evaluated the Th2-biased 
immune response to RSV in vitro and in vivo. Furthermore, we adoptively transferred 
mDCs that overexpressed IL-4Rα into adult mice to confirm the importance of IL-4Rα in 
the induction of Th2-biased immune responses to RSV. Our data demonstrate that high 
levels of IL-4Rα, as occurs in infancy, inhibits the maturation of CD11b+ mDCs; and, for 
the first time, establish a critical role for IL-4Rα on CD11b+ mDCs in initiating the Th2-
biased immunopathogenesis of neonatal RSV infection. 
 
 
Materials and Methods 
 
 
Mice 
 
BALB/c mice were purchased from Harlan laboratories and housed in a specific-
pathogen-free animal facility at the University of Tennessee Health Science Center 
(UTHSC), Memphis, Tennessee, USA. CD11c-specific IL-4Rα-/- mice (IL-4Rα-/- DC) or 
their littermates (IL-4Rα-/lox DC) were generated by crossing IL-4Rαlox/lox mice with 
CD11c-cre IL-4Rα-/- mice (gifts from Frank Brombacher, University of Cape Town, 
South Africa and generously donated by Debroski Herbert, University of California, San 
Francisco) (89). All mice were on BALB/c background. Breeders were time mated, and 
age-matched pups were used for all experiments. Neonatal mice were not identified for 
sex and both male and female were used for experiments. All animal experiments were 
performed according to Guidelines of Care and Use of Laboratory Animals and approved 
by UTHSC Animal Care and Use Committee. 
 
 
Experimental Design and RSV Infection 
 
Neonatal (5 days old) or adult mice (6 weeks old) were anesthetized using 
isoflurane and infected intranasally with human RSV strain A-2 (Advanced 
Biotechnologies; Columbia, MD, USA) (2 x 105 TCID50 per gram body weight) in 10µl 
(neonates) or 50µl (adults) of serum-free media (SFM; HyClone; Logan, UT, USA) or 
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SFM alone (Sham). A subset of the cohort was allowed to mature and was reinfected at 4 
weeks post primary infection. At 6 days post-reinfection, various endpoints were 
measured including lung function and histopathology, BALF cytokines or cellularity, and 
T cell profile. 
 
 
BMDCs Transduction and Transfer 
 
Bone marrow cells were isolated from tibia and femur of adult mice from 5-7 
week old mice as previously described (90)and then cultured in DC media (RPMI 1640 
(HyClone) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life 
Technologies, Carlsband, CA, USA), 100 U/ml penicillin (HyClone), 100 mg/ml 
streptomycin (HyClone), human FLT3 200 ng/mL (Tonbo biosciences, San Diego, CA, 
USA) for 6 days at a density of 1 x 106 per mL in a 6 well plate. BMDCs were then 
harvested and infected with 3rd generation lentiviral vectors (pLV-IL-4Rα-eGFP or 
control pLV-eGFP) ( Cyagen biosciences Inc, CA, USA) at a multiplicity of infection 
(MOI) 20 in Opti-MEM media (Life Technologies) and 5µg/ml of polybrene (Cyagen 
biosciences Inc) for 3 hours. These cells were then cultured in DC media for 4 days. 
Transduced cells were then infected with RSV at MOI 50 overnight, and CD11b+mDCs 
(CD11c+MHCIIhi CD11b+) were sorted using SH800 cell sorter (Sony Biotechnology 
Inc., San Jose, CA, USA). These cells were adoptively transferred intranasally into the 
lungs of mice (1x105 cells in 50 µl of SFM media). Control mice received 50 µl of SFM 
media. 
 
 
RSV Gene Expression in the Lung 
 
RSV gene expression in the lungs was quantified using real-time RT-PCR that 
correlates well with plaque assay or TCID50 assay (52, 86, 91). Lungs were isolated and 
total RNA was extracted using the Total RNA extraction kit (Qiagen; Valencia, CA, 
USA) according to the manufacturer's instructions. cDNA was synthesized using Oligo 
(dT) and SuperScript III first-strand synthesis system (Life Technologies; Carlsbad, CA, 
USA). Real-time PCR was performed using Platinum® SYBR® Green qPCR Supermix 
(Life Technologies) with the following primers: 
 
NS1 forward primer (5′-CACAACAATGCCAGTGCTACAA-3′) 
NS1 reverse primer (5′-TTAGACCATTAGGTTGAGAGCAATGT-3′) 
 
 
Cell Staining and Flow Cytometry 
 
To measure the expression of surface markers on pulmonary DCs, single cell 
suspensions were prepared from mouse lungs using gentleMACS™ Octo dissociator 
(Miltenyi Biotec Inc., San Diego, CA, USA) using standard protocol (86). Briefly, lungs 
were perfused and dissociated using gnetleMACS then digested using 1mg/ml 
collagenase I (Invitrogen; Thermo Fisher Scientific; Logan, UT, USA), and 150 μg/ml 
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DNase I (Sigma-Aldrich; St. Louis, MO, USA) by incubating at the 37oc incubator. Cell 
clumps and debris was removed by filtering through a 40 μm cell strainer (BD 
Biosciences, San Jose, CA, USA). Red blood cells were lysed using 1X RBC lysis buffer 
(eBioscience, San Diego, CA, USA) and then filtered again through 35 μm cell strainer to 
get single cell suspension. Single cell suspensions  were kept on RPMI-1640 (HyClone) 
containing 10% heat-inactivated fetal bovine serum (FBS; Life Technologies), 100 U/ml 
penicillin (HyClone), 100 mg/ml streptomycin (HyClone).A million cells were used for 
staining per animal, cells were counted using Acridine Orange/Propidium Iodide (AO/PI) 
stain and Cellometer (Nexcelom Bioscience LLC, Lawrence, MA, USA) Single cells 
were then stained with fixable viability dyes, antibodies to CD11c (N418), CD11b 
(M1/70; Biolegend, San Diego, CA,USA), CD103 (2E7), PDCA-1 (eBio 927), IL-4Rα 
(mIL-4R-M1; BD Biosciences), MHCII (M5/114.15.2), CD80 (16-10A1), and CD86 
(GL-1). All antibodies and dyes were from eBiosciences unless otherwise stated. The 
staining data were acquired on a FACS Canto II (BD Biosciences) flow cytometer and 
analyzed with FlowJo software (version 10; Tree Star; Ashland, OR, USA.). Since the 
mean fluorescence intensity (MFI )of IL-4Rα fluorescence minus one (FMO) controls 
were different among the mice at different ages (i.e., 1 day, 5 days, and 6 weeks old), the 
IL-4Rα MFI was normalized by subtracting MFI of the age-matched FMO controls from 
the actual values. 
 
To measure the T cell profile in the lung, single cells from lungs were isolated as 
aforementioned and stimulated for 5 hours at 37oC in RPMI-1640 (HyClone) containing 
10% heat-inactivated fetal bovine serum (FBS; Life Technologies), 100 U/ml penicillin 
(HyClone), 100 mg/ml streptomycin (HyClone), 5 ng/ml phorbol-12-myristate-13-acetate 
(PMA; Sigma-Aldrich), 500 ng/ml ionomycin (Sigma-Aldrich), and protein transport 
inhibitor (1 µl/106 cells; GolgiPlug, BD Biosciences). Cells were then stained with 
fixable viability dye, fixed with fixation buffer, permeabilized with permeabilization 
buffer, and labeled with antibodies to CD3 (17A2), CD4 (RM4-5; Biolegend), IFN 
(XMG1.2), and IL-4 (BVD6-24G2). All antibodies, dyes, and buffers were from 
eBiosciences unless otherwise stated. Flow data were then acquired and analyzed as 
aforementioned. Cells were gated on lymphocytes based on FSC/SSC properties, singlets, 
live cells, and then on the CD3 and CD4 double positive population. 
 
 
Bronchoalveolar Lavage Fluid (BALF) Cellularity 
 
BALF was isolated using 1 ml of PBS with 0.5% BSA. Cells were then counted 
using cellometer as mentioned previously. 20,000 cells from BALF were centrifuged 
onto slides using a cytospin. Cells were allowed to air -dry and stained with Hema-3 
staining kit (Thermo Fisher Scientific). Cells were then differentiated and 200 cells were 
counted for each animal by an unbiased observer using an EVOS microscope (Life 
Technologies; Thermo Fisher Scientific). 
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Pulmonary Function Test 
 
Airway resistance was assessed using the FlexiVent FX system (Scireq, Montreal, 
Canada) to increasing doses (0, 12.5, 25, 50 mg/ml) of methacholine (Sigma-Aldrich). 
Mice were anesthetized with ketamine/xylazine (180/10 mg/kg) and mechanically 
ventilated at a tidal volume of 10 ml/kg and a frequency of 2.5 Hz using a computer-
controlled piston ventilator. Resistance was calculated by recording pressure and volume 
of the airways using the single compartment model. All data were normalized to their 
individual baseline resistance values ((value-baseline)/baseline) and plotted as 
normalized resistance. 
 
 
Lung Histopathology 
 
Following euthanasia, hearts of mice were perfused with PBS and lungs were 
removed and gravity inflated with zinc formalin (Thermo Fisher Scientific) and then 
fixed for 24 hours. Lung tissues were then embedded in paraffin, sectioned, and stained 
with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS). Stained lung sections 
were visualized and images acquired using an EVOS microscope. Inflammation was 
semiquantitatively scored based on the following scale: 1- very mild, 2-mild, 3-moderate, 
4-severe in a blinded fashion. PAS staining was scored by a quantitative method (92). 
 
 
Cytokines in the Lung 
 
Cytokine levels, including IL-4, IL-12(p40), and IFN-γ, were measured in the 
BALF using a Milliplex kit (Millipore, Billerica, MA, USA) and Luminex system 
(Luminex; Austin, TX, USA) as per the manufacturer's instruction. Each sample was 
analyzed in duplicate. Raw data were plotted against a standard curve to interpolate 
unknowns via logistic regression. Values below the sensitivity of the assay were excluded 
from the graph. 
 
For IL-13 cytokine; lungs were isolated and quick froze using liquid nitrogen for 
later analysis. Frozen lungs were then homogenized using homogenizer and Tissue 
protein extraction solution (Thermo Fisher Scientific) with protease inhibitor(Thermo 
Fisher Scientific).The solution was spun down to collect supernatant, and protein 
concentration was measured using PierceTM BCA Assay Kit (Thermo Fisher Scientific). 
IL-13 in the lung homogenates was then quantified using a Mouse IL-13 Platinum ELISA 
kit (eBioscience). The detection limits for IL-4, IL-12(p40), IFN-γ, and IL-13 were 0.4, 
4.9, 0.9, and 2.8 pg/ml respectively. 
 
 
In vitro T Cell Activation Assay 
 
Pulmonary CD11b+ mDCs (CD11c+MHCII+CD11b+) were isolated first using 
CD11c Positive Selection Kit (Stemcell Technologies, Vancouver, Canada) and then 
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SH800 cell sorter (Sony Biotechnology Inc., San Jose, CA, USA) from lungs of neonatal 
mice 6 days post infection with RSV. CD4+ T cells were isolated from the spleen of naïve 
adult BALB/c mice with CD4 positive selection kit (Stemcell Technologies) and stained 
with 0.5 μM CFSE (Life Technologies). CFSE stained CD4+ cells (1x105) were then co-
cultured with CD11b+ mDCs (2x104) in the presence of 1 μg/ml CD3 antibody (17A2; 
eBiosciences) for 72 hours. Cells were stimulated, stained, and analyzed by flow 
cytometry to determine the Th subpopulations. The purity of isolated CD11b+ mDCs or 
CD4+ cells was greater than 90 percentage. 
 
 
Statistical Analyses 
 
Data were plotted as means ± SEM and analyzed using GraphPad Prism 6 
(GraphPad; La Jolla, CA, USA). Student’s t-test or Two-way ANOVA with Bonferroni 
posthoc tests were used to compare the means among groups, where appropriate. 
Differences were considered statistically significant if p < 0.05. 
 
 
Results 
 
 
Expression of IL-4Rα on Dendritic Cells Was Age Dependent 
 
In our previous study, we observed that the most significant downregulation of 
IL-4Rα following ASO treatment occurred in pulmonary DCs, and this downregulation 
correlated with decreased Th2-biased immunopathologies during RSV reinfection (51). 
To explore the role of IL-4Rα on mDCs, we first quantified its expression on various 
types of pulmonary DCs from mice at different ages using gating strategy: in (Figure  
2-1). Specifically, we measured expression of IL-4Rα on pulmonary CD11b+ mDCs 
(CD11c+MHCII+CD11b+), CD103+ mDCs (CD11c+MHCII+CD103+), and pDCs 
(CD11c+PDCA-1+) from neonatal (1 or 5 days old) or adult mice (6 weeks old) via flow 
cytometry (Figure 2-2A). The expression of IL-4Rα on CD11b+ mDCs declined as age 
increased, with 1 day old pups expressing the highest level (Figure 2-2B). Interestingly, 
IL-4Rα expression on CD103+ mDCs increased with age, with adults expressing the 
highest level (Figure 2-2C). Similar to CD11b+ mDCs, pDCs downregulated IL-4Rα 
expression while age increased (Figure 2-2D). These data suggest that the expression of 
IL-4Rα on pulmonary DCs is developmentally regulated and cell-specific. 
 
 
Deletion of IL-4Rα on CD11c+ Cells Attenuated Th2-biased Immune Responses 
upon RSV Reinfection 
 
Having confirmed that neonatal CD11b+ mDCs express elevated levels of IL-4Rα, 
we further examined the role of IL-4Rα on CD11b+ mDCs in polarizing the Th2-biased 
immune response to RSV. We used a mouse model in which IL-4Rα is specifically  
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Figure 2-1.  Gating strategy for pulmonary DCs. 
Single, live cells were first gated. mDCs were defined as CD11c+MHCII+ cells and 
further categorized into CD11b+ and CD103+ mDCs. pDCs were identified as 
CD11c+PDCA-1+ cells. The figure shown was a representative of lung cells from 1 day 
old pups. All gates were consistent among mice of different ages (i.e., 1 day, 5 days, or 6 
weeks old). 
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Figure 2-2. Expression of IL-4Rα on dendritic cells was age dependent. 
Lung DCs from neonatal (1 or 5 days old) or adult mice (6 weeks old) were analyzed by 
flow cytometry for the surface expression of IL-4Rα. (A)Flow cytometric histogram 
graphs showing a representative example of IL-4Rα expression on DC subsets.(B) IL-
4Rα MFI on CD11b+ mDCs. (C) IL-4Rα MFI on CD103+ mDCs. (D) IL-4Rα MFI on 
pDCs. MFI = mean fluorescence intensity. Shaded histograms represent FMO controls. 
Data are representative of 3 independent experiments with four to five mice per group; 
*p<0.05. 
  
 19 
deleted on CD11c+ cells (IL-4R-/- DC) by crossing IL-4Rαlox/lox mice with CD11cCre IL-
4Rα-/- mice. In these mice, the expression of IL-4Rα is decreased on mDCs and alveolar 
macrophages, but not on T cells (Figure 2-3). The littermate controls (IL-4Rα-/lox DC) 
have one copy of intact IL-4Rα. IL-4Rα-/- DC and IL-4Rα-/lox DC neonatal mice were 
infected with RSV (IL-4Rα-/-DC RR and IL-4Rα-/lox DC RR) or media (IL-4Rα-/-DC Sham or 
IL-4Rα-/lox DC Sham) at 5 days of age and reinfected at 4 weeks post primary infection. At 
6 days post reinfection, we analyzed the CD4+ T cell responses from the lungs of these 
mice. As expected, the IL-4Rα-/lox DC RR mice that had one copy of intact Il-4Rα mounted 
a Th2-biased immune response upon RSV reinfection, although the magnitude of this 
Th2-bias was smaller than BALB/c mice as previously published (51). More importantly, 
we observed a significant decrease in the percentage of CD4+ IL-4+ T cells in the IL-4Rα-
/-DC RR mice compared to IL-4Rα-/lox DC RR mice (Figure 2-4A). There was also a 
reduction in CD4+ IFN-γ+ IL-4+ T cells in IL-4Rα-/-DC RR mice vs. IL-4Rα -/lox DC RR 
mice (Figure 2-4A). 
 
This reduction in Th2 cells was accompanied with a decrease in the IL-13 (Table 
2-1) in lung homogenates. IL-4 was very low in both groups. While no difference was 
observed in the percentage of CD4+ IFN-γ+ T cells between the RSV infected groups, we 
did observe an elevation in IL-12p40 levels in the BALF of IL-4Rα-/-DC RR mice vs. IL-
4Rα-/lox DC RR (Table 2-1). These results were not due to a difference in relative viral 
gene expression of RSV (Figure 2-4B) or baseline numbers of DCs during initial 
infection (Figure 2-5). These data indicate that IL-4Rα on CD11b+ mDCs plays a role in 
the Th2-biased immune response to neonatal RSV infection in vivo. 
 
 
Deletion of IL-4Rα on CD11c+ Cells Protected Mice from Immunopathophysiology 
upon RSV Reinfection 
 
In addition to the pulmonary CD4+ T cell responses, we also examined 
pathophysiological endpoints including BALF cellularity and pulmonary function and 
pathology in IL-4Rα-/- DC RR and IL-4Rα-/lox DC RR mice. We observed substantially 
reduced inflammatory responses in the airways of IL-4Rα-/- DC RR mice as evidenced by 
reduced total cells, macrophages, and eosinophils in the BALF compared to IL-4Rα-/lox DC 
RR mice (Figure 2-6A). As shown in (Figure 2-6B), RSV induced airway 
hyperreactivity (AHR) in IL-4Rα-/lox DC RR mice, whereas airway resistance in IL-4Rα-/- 
DC RR mice was no different than sham controls. No significant differences in resistance 
were detected between groups of sham infected mice. Peribronchiolar and perivascular 
inflammation were significantly reduced in IL-4Rα-/- DC RR vs. IL-4Rα-/lox DC RR mice 
(Figure 2-6C). Strikingly, there was little-to-no mucus production in the airways of IL-
4Rα-/- DC RR, while significant amounts of airway mucus were obvious in IL-4Rα-/lox DC 
RR mice (Figure 2-6D). This observation is consistent with the fact that airway 
resistance in IL-4Rα-/- DC RR mice was no different from sham-infected mice. The 
decrease in airway inflammation, AHR, and mucus hyperproduction in IL-4Rα-/- DC RR 
mice suggests that elevated IL-4Rα expression on CD11b+ mDCs is partially responsible 
for the immunopathophysiology upon RSV reinfection. 
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Figure 2-3. IL-4Rα expression on pulmonary CD11b+ mDCs, CD103+ mDCs, and 
AMs was decreased in CD11c+ specific, IL-4Rα deficient mice. 
IL-4Rα-/- DC and IL-4Rα-/lox DC mice at 5 days of age were infected with RSV ; and IL-4Rα 
expression at 4 dpi was measured via flow cytometry on pulmonary CD11b+mDCs 
(CD11c+MHCII+F4/80-CD11b+), CD103+ mDCs (CD11c+MHCII+F4/80-CD103+), 
alveolar macrophages (AMs, CD11c+F4/80+), CD4+ T cell, and CD8+ T cells. n=3 mice 
per group. 
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Figure 2-4. Deletion of IL-4Rα on CD11c+ cells attenuated Th2-biased immune 
responses upon RSV reinfection. 
IL-4Rα-/- DC or IL-4Rα-/lox DC mice were infected at 5 days of age and reinfected with RSV 
4 weeks later (IL-4Rα-/-DC RR and IL-4Rα-/lox DC RR, respectively). Control mice were 
sham infected (IL-4Rα-/-DC Sham and IL-4Rα-/lox DC Sham). Pulmonary Th profile was 
measured via flow cytometry at 6 days post-reinfection and viral gene expression via 
real-time RT-PCR at 4 days post primary infection was calculated. (A) Percentage (upper 
panel) and numbers (middle panel) of pulmonary CD4+ T cells expressing IFN-γ, IL-4, or 
both IFN-γ and IL-4. The bottom panel displays representative flow plots. (B) Relative 
expression of RSV NS1 gene in the lung at 4 days post primary infection. Data are 
representative of 3 independent experiments with four to five mice per group; *p<0.05. 
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Table 2-1. Deletion of IL-4Rα on CD11c+ cells attenuated Th2-biased cytokine 
responses in the lung upon RSV reinfection. 
 
Cytokines 
(pg/ml) 
IL-4Rα-/lox DC 
Sham 
IL-4Rα-/-DC 
Sham 
IL-4Rα-/lox DC 
RR 
IL-4Rα-/-DC 
RR 
IFN- B.D. B.D. 51.9±15.9 88.9±14.4 
IL-4 B.D. B.D. 1.1±0.2 1.2±0.2 
IL-12p40 B.D. B.D. 9.2±3.4 21.0±4.3* 
IL-13 21.0±2.1 19.3±4.5 27.7±1.6# 18.9±2.1* 
 
Notes: IL-4Rα-/lox DC or IL-4Rα-/- DC mice were infected at 5 days of age and reinfected 
with RSV 4 week later (IL-4Rα-/lox DC RR or IL-4Rα-/- DC RR, respectively). Control mice 
received serum-free viral growth media (IL-4Rα-/lox DC Sham or IL-4Rα-/- DC Sham). 
Cytokines were measured in BALF (IFN-γ, IL-4, and IL-12p40) or lung homogenates 
(IL-13) at 6 days post reinfection and are reported in pg/ml. n = 4-5 mice per 
group,*p<0.05 vs. IL-4Rα-/lox DC RR. #p<0.05 vs. IL-4Rα-/lox DC Sham or IL-4Rα-/- DC 
Sham. B.D.: below the detection limit. 
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Figure 2-5. The amount of mDCs, CD11b+ mDCs, and CD103+ mDCs did not 
change in CD11c+ specific, IL-4Rα deficient mice. 
The amount of mDCs (CD11c+MHCII+), CD11b+mDCs (CD11c+MHCII+CD11b+), 
CD103+mDCs (CD11c+MHCII+CD103+) was quantified in 5 days old, CD11c+ specific, 
IL-4Rα deficient mice (IL-4Rα-/- DC) and their littermates (IL-4Rα-/lox DC) via flow 
cytometry. n=3-4 mice per group. 
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Figure 2-6. Deletion  of IL-4Rα on CD11b+ mDCs protected mice from 
immunopathophysiology upon RSV reinfection. 
IL-4Rα-/- DC or IL-4Rα-/lox DC mice were infected and reinfected with RSV as previously 
described. BALF cellularity, airways resistance in response to methacholine challenge, 
and histology were performed at 6 days post-reinfection. (A) BALF cellularity. Macs: 
macrophages, Lymph: lymphocytes, Neutro: neutrophils, Eos: eosinophils. (B) Airway 
resistance. (C) H&E stained lung sections and inflammation score. Arrowheads point to 
cellular infiltrates. (D) PAS stained lung sections and PAS score. Arrowheads point to 
mucus. Scale bar = 400m in the upper panels. The bottom panels are images taken under 
higher magnification of the selected area in the upper panel (inset box). Scale bar = 
100m in the bottom panels. Data are representative of 2 independent experiments with 
four to five mice per group; *p<0.05. 
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Absence of IL-4Rα on CD11b+mDCs Dampened Th2 Responses to RSV Infection in 
vitro 
 
While the expression of IL-4Rα was decreased on neonatal CD11b+ mDCs in the 
IL-4Rα-/-DC mice, it was also decreased on CD103+ mDCs and alveolar macrophages 
(Figure 2-3). To examine the role of IL-4Rα specifically on CD11b+ mDCs to induce 
Th2biased immune response to RSV, we performed in vitro T cell activation assays. 
Pulmonary CD11b+ mDCs were isolated from RSV-infected neonatal IL-4Rα-/- DC or IL-
4Rα-/lox DC mice. These cells were subsequently co-cultured for 3 days with splenic CD4+ 
T cells isolated from naïve adult BALB/c mice, and T cell phenotypes were then 
measured by flow cytometry. As expected, neonatal CD11b+ mDCs from IL-4Rα-/lox DC 
mice induced a substantial amount of Th2 cells (CD4+IL-4+); and mimicking our in vivo 
data, CD11b+ mDCs from IL-4Rα-/-DC mice induced significantly less amount of Th2 
cells (Figure 2-7B) and decreased ratio of Th2/Th1 (CD4+IL-4+/ CD4+IFN-γ+) cells 
(Figure 2-7C). These data suggest that IL-4Rα expression on CD11b+ mDCs promotes 
Th2-biased immune responses to RSV. 
 
 
Loss of IL-4Rα Expression on CD11b+ mDCs Enhanced Their Maturation 
 
To delineate the mechanism by which IL-4Rα on CD11b+ mDCs induced Th2-
biased responses to RSV in neonates, we measured the expression of maturation markers 
(CD80 and CD86) on CD11b+ mDCs. Wild-type neonates (NR) and adults (AR) or IL-
4Rα-/- DC neonates (IL-4Rα-/- DC NR) were infected with RSV, and the expression of CD80 
and CD86 was measured on pulmonary CD11b+ mDCs by flow cytometry. Consistent 
with previous studies (29, 71), neonatal CD11b+ mDCs were less mature (i.e. reduced 
expression of CD80 and CD86) compared to their adult counterparts during RSV 
infection (Figure 2-8A&B). In the absence of IL-4Rα, the expression of CD80 and CD86 
was significantly enhanced on CD11b+ mDCs (IL-4Rα-/- DCNR compared to NR mice; 
Figure 2-8A&B). These data suggest that elevated expression of IL-4Rα on neonatal 
CD11b+ mDCs suppresses the ability of these cells to mature in response to RSV 
infection, resulting in Th2-biased adaptive immune response. 
 
 
Overexpression of IL-4Rα on Adult mDCs Exacerbated Th2 Responses to RSV 
Infection in vivo 
 
Expression of IL-4Rα on CD11b+ mDCs declines significantly with age. To 
further confirm the pathogenic role of IL-4Rα, we overexpressed IL-4Rα on adult mDCs.  
Specifically, we transduced adult bone marrow-derived dendritic cells (BMDCs) with IL-
4Rα (pLV-IL-4Rα-eGFP) or eGFP (pLV-eGFP) expressing lentivirus. Successful 
transduction was verified using flow cytometry (Figure 2-9). CD11b+ mDCs that were 
positive for eGFP were then sorted and adoptively transferred to the lungs of naïve adult 
mice. One week later, these mice were infected with RSV. Six days post-infection, we 
analyzed pulmonary CD4+ T cell responses. Overexpression of IL-4Rα on adult CD11b+  
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Figure 2-7. Absence of IL-4Rα on CD11b+ mDCs dampened Th2 responses to 
RSV infection in vitro. 
Neonatal IL-4Rα-/- DC and IL-4Rα-/lox DC were infected with RSV. CD11b+ mDCs were 
isolated from these mice at 6 days post infection and cultured with CD4+ T cells purified 
from spleens of naïve, adult BALB/c mice. Th profile was measured after 72 hr co-
culture using flow cytometry. (A) Percentage of pulmonary CD4+ T cells expressing IFN-
γ. (B) Percentage of pulmonary CD4+ T cells expressing IL-4. (C) Ratio of pulmonary 
CD4+ T cells expressing IL-4 and IFN- γ. Data are representative of 2 independent 
experiments with three samples per group; *p<0.05. 
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Figure 2-8. Loss of IL-4Rα on CD11b+ mDCs enhances their maturation response 
to RSV. 
Neonatal or adult WT mice and neonatal IL-4Rα-/- DC mice were infected with RSV. 
Maturation markers (CD80 and CD86) and MHCII were measured on lung CD11b+ 
mDCs via flow cytometry. (A) MFI of CD80 on CD11b+ mDCs. (B) MFI of CD86 on 
CD11b+ mDCs. (C) MFI of MHCII on CD11b+ mDCs.(D) Flow cytometric histogram 
showing representative expression of CD80, CD86, and MHCII on CD11b+ mDCs. Data 
are representative of 3 independent experiments with four to five mice per group; 
*p<0.05. 
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Figure 2-9. GFP and IL-4Rα expression on BMDCs was increased after 
transduction. 
BMDCs purified from adult mice were transduced with lentiviral vectors (either pLV-IL-
4Rα-eGFP or control pLV-eGFP), and GFP and IL-4Rα expression was measured via 
flow cytometry 5 days post transduction. 
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mDCs (pLV-IL-4Rα-eGFP) resulted in a lower percentage but no significant change in 
the number of CD4+IFN-γ+ T cells (Figure 2-10A&B). A higher percentage and number 
of CD4+IL-4+ T cells were observed when IL-4Rα was overexpressed on adult CD11b+ 
mDCs compared to the control groups (Figure 2-10A&B). There was no change in the 
percentage of CD4+IFN-γ+IL-4+ cells with overexpression of IL-4Rα on adult CD11b+ 
mDCs, but there was an increase in the number of these cells (Figure 2-8B). 
 
 
Discussion 
 
Infants are particularly vulnerable to severe RSV infection; both human and 
animal studies implicate a Th2-biased immune response in the pathogenesis of RSV in 
infants (42, 43). In particular, single nucleotide polymorphisms in the IL-4Rα gene that 
increase the receptor response to its cytokines (IL-4 or IL-13) are associated with 
increased IgE production, hospitalization rates due to RSV infection, and susceptibility to 
asthma (79, 93). Pharmacological downregulation of IL-4Rα in the lung is protective 
against RSV disease in neonatal mice and effective in preventing Th2-biased 
immunopathogenesis (51). In the current study, we observed increased expression of IL-
4Rα on pulmonary CD11b+ mDCs in neonatal compared to adult mice. Deletion of IL-
4Rα on neonatal CD11c+ cells (including CD11b+ mDCs and other cells) resulted in a 
significant reduction in Th2 polarization, RSV-associated airway hyperreactivity, 
inflammation and eosinophilia following RSV reinfection in vivo. This was accompanied 
by an increase in IL-12 production. In vitro T cell activation assays demonstrated the 
specificity of IL-4Rα on neonatal CD11b+ mDCs in the induction of Th2 responses to 
RSV. Since adult CD11b+ mDCs express significantly less IL-4Rα, complimentary 
experiments in which adult CD11b+ mDCs were made to overexpress IL-4Rα were also 
performed. Overexpression of IL-4Rα on adult CD11b+ mDCs and the transfer of these 
cells into the lungs of adult mice prior to RSV infection were able to recapitulate the Th2-
biased immunopathogenesis observed in neonatal mice. More mechanistically, we 
demonstrated that pulmonary CD11b+ mDCs were less mature in neonates compared to 
adults in response to RSV infection and that deletion of IL-4Rα on CD11b+ mDCs 
enhanced their maturation altering Th2/Th1 immune responses to RSV. 
 
The maturation status of DCs is important for their function; and the 
costimulatory molecules, CD80 and CD86, are thought to be essential as the second 
signal for T cell activation. Here, we demonstrated that the level of CD80 and CD86 on 
CD11b+ mDCs was associated with the axis of CD4+ T cell differentiation (i.e. Th1 vs. 
Th2). Neonatal CD11b+ mDCs expressed less CD80 and CD86 than their adult 
counterparts (Figure 2-8A&B) and induced fewer Th1 cells in response to RSV infection 
(52). Interestingly, CD103+ mDCs, which mainly activate CD8+ T cells, have also been 
shown to be immature in neonates compared to adults; and the maturation status of 
CD103+ mDCs influences the epitope hierarchy of CD8+ T cells in response to RSV 
infection (94). Thus, it is exciting to speculate that maturation status of CD11b+ mDCs 
may also dictate epitope hierarchy of CD4+ T cells in response to RSV infection – a 
concept that we are currently exploring. We further demonstrated that the expression of  
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Figure 2-10. Overexpression of IL-4Rα on adult CD11b+ mDCs exacerbated Th2 
responses to RSV infection in adult mice. 
BMDCs were isolated from adult mice, transduced with pLV-IL-4Rα-eGFP or pLV-
eGFP control, and infected with RSV. CD11b+ mDCs that were positive for eGFP were 
sorted and adoptively transferred into the lungs of adult mice. These mice were then 
infected with RSV, and six days later pulmonary Th subsets were quantified. (A) 
Percentage of CD4+ T cells expressing IFN-γ, or IL-4, or both IFN-γ and IL-4. (B) 
Number of CD4+ T cells expressing IFN- γ, or IL-4, or both IFN-γ and IL-4. Data are 
representative of 2 independent experiments with three to four mice per group; *p<0.05. 
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CD80 and CD86 on CD11b+ mDCs was partially regulated by the expression of IL-4Rα, 
since deletion of IL-4Rα on CD11b+ mDCs restored some expression of CD80 and CD86 
following RSV infection. The mechanism(s) via which IL-4Rα is developmentally 
regulated and how IL-4Rα regulates the expression of CD80 and CD86 are currently 
unclear and warrant further investigation. 
 
The ratio of Th2/Th1 cells decreased by 50% in the IL-4Rα-/- DC mice compared to 
IL-4Rα-/lox DC mice both in vivo and in vitro (Figure 2-4&2-7). While the reduction is not 
massive, it is significant. The reduction in Th2/Th1 ratio was accompanied by improved 
lung function and significantly decreased lung pathologies. We have observed this 
phenomenon in our previous publications (51, 52). A subtle reduction in IL-4Rα on Th 
cells and DCs completely abolished lung dysfunction following RSV reinfection. We 
think the pathology is determined by the balance of Th1/Th2 immune responses and that 
a small shift from the Th2 biased immune response is all that is necessary to change the 
lung pathology.  
 
As with our previous studies (51, 52), we observed a CD4+ T cell population 
expressing IFN-+ and IL-4+ following RSV reinfection. Initially, these cells were 
thought to be pre-Th1/Th2 cells that are in the intermediate stage during the commitment 
process of Th1/Th2 cells (95, 96). However, recent data demonstrate that this phenotype 
is acquired after full differentiation and that these cells support both type 1 and type 2 
inflammatory responses (97). IL-4Rα deletion on CD11b+ mDCs decreased the 
percentage of these cells in the lungs of mice following RSV reinfection. The exact role 
of these cells in RSV pathogenesis remains elusive, but the reduction of these cells has 
consistently coincided with reduced pulmonary immunopathophysiology upon RSV 
reinfection here and in our previously published work (51, 52). 
 
Although deletion of IL-4Rα on CD11b+ mDCs did not alter the percentage of 
pulmonary Th1 (CD4+ IFN-+) cells following RSV reinfection, there was an increase in 
the level of IL-12p40 (a Th1 cytokine) in the BALF (Table 2-1). The elevated IL-12p40 
level may result from the decreased IL-13, as IL-13 has been previously shown to inhibit 
IL-12 production via IL-4Rα signaling (98). 
 
A limitation of our in vivo studies was that IL-4Rα was not specifically deleted on 
CD11b+ mDCs. In fact, IL-4Rα was deleted on CD11c+/hi cells including alveolar 
macrophages (AMs), CD11b+ mDCs, and CD103+ mDCs; and on CD11c+/lo cells 
including pDCs, NK cells, B cells, and CD8+ T cells (99). However, we believe that our 
in vitro data (T cell activation assays with neonatal CD11b+ mDCs) and in vivo data 
(adoptive transfer of adult CD11b+ mDCs that overexpress IL-4Rα) and data from the 
literature (summarized below) argue for the specific role of IL-4Rα on CD11b+ mDCs in 
RSV immunopathogenesis. IL-4Rα is deleted on CD103+ mDCs in our model; however, 
we speculated that the deletion of IL-4Rα on CD103+ mDCs most likely has minimal 
effect on the Th2-biased response to RSV infection due to the following reasons. CD103+ 
mDCs mainly activate CD8+, not CD4+, T cells (67, 68). Additionally, neonatal CD103+ 
mDCs express significantly less IL-4Rα compared to their adult counterparts, whereas 
the Th2-bias is only observed in neonates. In the Cryptococcus infection model, deletion 
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of IL-4Rα specifically on AMs (LysMCreIL-4Rα-/lox) was unable to alter the Th2 
responses (100), suggesting that IL-4Rα expression on AMs has no effect on Th2 
polarization. As to the cells expressing low levels of CD11c, we and others (89) have 
observed inefficient Cre function and thus inefficient deletion of IL-4Rα in these cells, 
including B (89) and T cells (Figure 2-3). 
 
In summary, we have demonstrated a novel age-dependent mechanism (IL-4Rα 
on CD11b+ mDCs) responsible for the Th2-biased immunopathogenesis during neonatal 
RSV infection. We have shown that IL-4Rα expression on CD11b+ mDCs is 
developmentally regulated, and higher expression of IL-4Rα is associated with a less 
mature phenotype of the CD11b+ mDCs in response to RSV infection, resulting in Th2-
biased immune responses. The deletion of IL-4Rα on CD11b+ mDCs significantly 
decreased the Th2-biased immunopathogenesis during RSV infection by allowing 
enhanced maturation of CD11b+ mDCs. Our data suggest that modulating IL-4Rα 
signaling on CD11b+ mDCs may be a strategy for developing RSV therapeutics and that 
vaccine strategies should investigate such signaling in determining efficacy. 
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CHAPTER 3.    LIMITED TYPE I IFNS AND PLASMACYTOID DENDRITIC 
CELLS DURING NEONATAL RESPIRATORY SYNCYTIAL VIRUS 
INFECTION PERMIT IMMUNOPATHOGENESIS UPON REINFECTION* 
 
 
Introduction 
 
 Though it is clear that the adaptive arm of the immune system and its key 
molecules play vital roles in the immunopathogenesis of RSV disease, adaptive immune 
responses are first instructed by the innate response. Data generated from human primary 
cells and adult animal models shed light on the innate immune responses to RSV. In 
particular, several laboratories have demonstrated that type I IFNs; mainly IFN-α and 
IFN-β, and their major producers pDCs are important in protection from RSV disease. It 
has been reported that RSV stimulates pDCs isolated from human peripheral blood 
mononuclear cells (101, 102) or murine bone marrow-derived pDCs (103, 104) to 
produce type I IFNs ex vivo. Furthermore, several publications have demonstrated that 
RSV infection of adult mice induces pulmonary type I IFNs in vivo (75, 105) and that 
intranasal administration of recombinant IFN-α significantly reduced lung viral load, 
inflammation, weight loss, and clinical illness scores of RSV-infected adult mice (106). It 
has also been demonstrated that RSV infection induces recruitment of pDCs to the lungs 
of adult mice, and the depletion of pDCs results in increased pulmonary viral load and 
immunopathology (75). 
 
Despite the apparent roles of type I IFNs and pDCs in determining RSV 
morbidity, there are few studies investigating pDCs in infants. Data demonstrate that 
pDCs are recruited to the mucosal compartment of the airways and are readily detectable 
in nasal washes from children infected with RSV (107); however, there are very low 
levels of type I IFNs in nasal washes from RSV-infected infants (76). Recent data from 
Stuart Turvey’s group support these findings and demonstrate that pDCs isolated from 
cord blood of healthy term infants are unable to mount robust type I IFN responses upon 
RSV infection ex vivo when compared to pDCs from healthy adults, suggesting that 
human infant pDCs are immature and/or less responsive at birth (87). 
 
The present study is the first attempt, to our knowledge, to characterize the role of 
type I IFNs and pDC responses in the immunopathogenesis during RSV reinfection using 
a neonatal mouse model. Our data demonstrate that neonatal mice mounted limited type I 
IFNs and pDC responses during primary RSV infection. Treatment of neonatal mice with 
IFN-α or adoptive transfer of adult pDCs prior to RSV infection significantly reduced 
Th2-biased immunopathophysiology, strongly suggesting that limited type I IFN and  
 
 
-------------------------- 
*Adapted with permission. Cormier, SA, Shrestha B, Saravia J, Lee GI, Shen L, 
DeVincenzo JP, Kim YI, and You D. Limited type I interferons and plasmacytoid 
immunopathogenesis upon reinfection. 2014. J. Virol. 88: 9350-9360 
immunopathophysiology in response to RSV infection.  
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pDC responses during infancy permit the development of a Th2-biased-dendritic cells  
during neonatal respiratory syncytial virus infection permit 
 
 
Materials and Methods 
 
 
Mice 
 
BALB/c mice were purchased from Harlan Laboratories (Indianapolis, IN, USA) 
and maintained in specific-pathogen-free facilities at Louisiana State University Health 
Sciences Center (LSUHSC, New Orleans, LA, USA) and University of Tennessee Health 
Science Center (UTHSC, Memphis, TN, USA). Breeders were time-mated and pups born 
on the same date were used for experiments. A set of pups were allowed to mature to 6-8 
weeks of age and were then used as adult controls or the cell source of pDCs for adoptive 
transfer studies. 
 
All animal protocols were prepared in accordance with the Guide for the Care and 
Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee at LSUHSC or UTHSC. 
 
 
IFN-α Treatment 
 
Mouse recombinant IFN-α was purchased from PBL Interferon Source 
(Piscataway, NJ, USA). Sixteen hours prior to RSV infection, 2 x 103 units of IFN-α was 
instilled intranasally into pups in 10 µl of PBS containing 0.1% BSA. Control pups (NS) 
received 10 µl of PBS containing 0.1% BSA. 
 
 
Purification of pDCs or CD11c+ Cells and Adoptive Transfer 
 
pDCs were purified from adult spleens using OptiPrep gradient medium (Sigma-
Aldrich, St. Louis, MO, USA) and a negative selection kit from Miltenyi Biotec Inc. 
(Auburn, CA, USA). Briefly, a single cell suspension of spleens was prepared using 
gentleMACS™ Octo Dissociator and the spleen dissociation kit. Spleen cells were then 
suspended in HBSS containing 15% OptiPrep and overlaid onto 11.5% OptiPrep and 
centrifuged. Low density cells consisting of mostly dendritic cells were collected and 
subjected to further purification for pDCs using the negative selection kit as per 
manufacturer’s instructions. The purity of the pDCs isolated was verified by flow 
cytometry and was above 85%. For adoptive transfer studies, pDCs were purified as 
above and suspended in 10 µl serum-free medium (SFM; SFM4MegaVir™; HyClone, 
Logan, UT, USA); and 3 x 104 pDCs were intranasally instilled into pups 16 h prior to 
RSV infection. Control pups received 10 µl SFM. 
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CD11c+ cells were purified from adult spleens for adoptive transfer. Adult 
splenocytes were isolated as above and CD11c+ cells selected using a positive selection 
kit from Stemcell Technologies (Vancouver, British Columbia, Canada). The purity of 
isolation was above 90%. CD11c+ cells were suspended in 10 µl SFM; and 3 x 104 cells 
were instilled intranasally into pups 16 h prior to RSV infection. Control pups received 
10 µl SFM. 
 
 
Assessment of Pulmonary Viral Load 
 
At four days post-initial RSV infection, lungs were isolated, weighed, and frozen 
until analysis by either plaque assay (108) or real time RT-PCR methods (91). For plaque 
assays, supernatants from centrifuged lung homogenates were added onto Vero cells and 
overlaid with 0.3% agarose (MP Biochemicals, Santa Ana, CA, USA). Cells were 
incubated for three days, fixed with 1% formaldehyde, and stained with 0.5% neutral red 
(Sigma-Aldrich). The plaques were counted and viral load were expressed as plaque-
forming units (PFU)/g lung tissue. 
 
For real time PCR, RNA was isolated from frozen lungs using Qiagen (Valencia, 
CA) RNeasy plus mini kit as per the manufacturer’s instructions. Real time RT-PCR was 
then performed using SuperScript® III Platinum®One-Step qRT-PCR Kit from Life 
Technologies (Carlsbad, CA, USA). The primers (91) used for the reaction were: 
 
NS1, forward primer: 5’-CACAACAATGCCAGTGCTACAA-3’  
NS1, reverse primer: 5’-TTAGACCATTAGGTTGAGAGCAATGT-3’ 
 
 
Cell Staining and Flow Cytometry 
 
To measure pDC levels in the lung, single cells were isolated and labeled with 
fixable viability dye and antibodies to CD11c (N418) and PDCA-1 (eBio129c). Stained 
cells were then assayed on a Canto II flow cytometer (BD Biosciences, Franklin Lakes, 
NJ, USA), and flow data were analyzed and plotted with FlowJo software (version 7.6.5 
for Windows; Tree Star; Ashland, OR, USA). Singlet live cells were gated before any 
further analysis. All buffers, viability dyes, and antibodies were purchased from 
eBiosciences unless otherwise stated. 
 
To determine the CD4+ T cell populations in the lung, single cells were isolated as 
above and stimulated for 5 h in RPMI-1640 (HyClone) containing 10% heat inactivated 
fetal bovine serum (FBS; Life Technologies), 100 U/ml penicillin (HyClone), 100 mg/ml 
streptomycin (HyClone), 5 ng/ml phorbol-12-myristate-13-acetate (PMA; Sigma-
Aldrich), and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of a protein transport 
inhibitor (1 µl/106 cells; GolgiPlug, BD Biosciences, Franklin Lakes, NJ). After 
stimulation, the cells were stained with fixable viability dye, fixed and permeabilized, 
and labeled with antibodies to CD3 (17A2), CD4 (RM4-4; Biolegend), IFN-γ (XMG1.2), 
and IL-4 (BVD6-24G2). Flow data were then acquired, analyzed, and plotted as above. 
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Cytokine Measurement 
 
Real-time PCR was performed to measure the kinetics of IFN-α expression in the 
lung. Total lung RNA was isolated using Quick-RNA MiniPrep from Zymo Research 
(Irvine, CA, USA) and then real time RT-PCR was performed using SuperScript® III 
Platinum®One-Step qRT-PCR Kit (Life Technologies). The primers used for the reaction 
were: 
 
IFN-α4, forward primer: 5’-TGATGAGCTACTACTGGTCAGC-3’  
IFN-α4, reverse primer: 5’-GATCTCTTAGCACAAGGATGGC-3’ 
 
To measure protein levels of type I IFNs in the lung, total lung proteins were 
isolated using T-PER Tissue Protein Extraction Reagent and quantified using BCA 
Protein Assay Reagent (Thermo Fisher Scientific). Levels of IFN-α and IFN-β were then 
measured using ELISA kits as per the manufacturer's instruction (PBL Interferon 
Source). The limit of detection was 12.5 pg/ml for IFN-α and 15.6 pg/ml for IFN-β. All 
data presented are above the limit of detection. 
 
The level of other cytokines in the BALF including IFN-γ, IL-12 (p40), IL-4, and 
IL-13 were measured using Milliplex mouse cytokine/chemokine assay kit (Millipore 
Corporation; Billerica, MA, USA) on the Bio-plex system (Bio-Rad Laboratories; 
Hercules, CA, USA). Data outside of the sensitivity level of detection were excluded. 
 
 
Statistics 
 
Data were plotted as means ± standard errors (SEM) and analyzed using Prism 6 
(GraphPad Software; La Jolla, CA, USA). Student’s t-test was used for all mouse studies 
except for the pulmonary function test, which was analyzed by two-way analysis of 
variance (ANOVA) and Bonferroni posthoc tests. Each figure represents one experiment. 
In the legend, n represents the number of animals and every experiment was repeated at 
least twice. Differences were considered significant if p < 0.05. 
 
 
Results 
 
 
RSV Infection Induced Limited Type I IFNs and pDC Responses in Neonatal Mouse 
Lungs 
 
Type I IFNs are important anti-viral cytokines induced during viral infections. We 
measured the amount of type I IFNs in the lung at various time points post-RSV 
infection. Neonates were infected with RSV and lungs were isolated at 5 h, 1 d, 2 d, 4 d 
and 6 d post-infection (dpi). The expression of IFN-α was measured at these time points  
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using real-time RT-PCR. Although it has been reported that RSV A2 and clinical strains 
are capable of inhibiting type I IFNs expression in human cells ex vivo (109), we 
observed induction of IFN-α in the lungs of RSV-infected mice as early as 5 h post-
infection and a peak in IFN-α at 1 and 2 dpi (Figure 3-1A). We further measured protein 
levels of type I IFNs, including both IFN-α and IFN-β, in the lung homogenates of RSV-
infected neonatal vs. adult mice. IFN-β was slightly, but significantly, increased at 1 dpi 
in neonates (Figure 3-1C); neonate RSV vs. neonate Sham: 11.84 ± 1.22 vs. 5.57 ± 0.57 
ng/g lung protein); whereas IFN-α was not significantly different from sham-infected 
neonates (Figure 3-1B); neonate RSV vs. neonate Sham: 5.51 ± 0.51 vs. 4.35 ± 0.39 ng/g 
lung protein). More importantly, adults infected with RSV induced significantly greater 
amounts of IFN-α (Figure 3-1B); adult RSV vs. adult Sham: 76.16 ± 5.59 vs. 3.77 ± 0.45 
ng/g lung protein) and IFN-β (Figure 3-1B); adult RSV vs. adult Sham: 42.25 ± 2.92 vs. 
8.14 ± 1.15 ng/g lung protein) compared to sham-infected adults at 1 dpi. Both IFN-α and 
IFN-β from RSV-infected adults were significantly higher than in RSV-infected 
neonates. 
 
Numerous reports have shown that pDCs are a major source of type I IFNs during 
viral infections (110, 111); we, therefore, compared the kinetics of pDCs during RSV 
infection in neonatal vs. adult mice. Neonates or adults were infected with RSV and the 
number of pDCs in the lung was measured at 5 h, 7 d, 14 d, and 21 dpi using flow 
cytometry (Figure 3-2). RSV infection induced recruitment of pDCs to the lung, with 
levels peaking at 7 dpi and declining to baseline levels by 21 dpi in both adults and 
neonates (Figure 3-2A&B). The frequency of pDCs was substantially greater at 7 dpi in 
RSV-infected adults compared to sham-infected adults (Figure 3-2D; 6.16 ± 0.68 vs. 
0.33 ± 0.06%); whereas there was only a slight, but significant, increase in the frequency 
of pDCs from RSV-infected neonates compared to sham-infected neonates (Figure 3-2C; 
0.38 ± 0.05 vs. 0.26 ± 0.01%). Additionally, the frequency of pDCs was significantly 
greater at 7 dpi in adults infected with RSV (6.16 ± 0.68 %) compared to neonates 
infected with RSV (0.38 ± 0.05%) (Figure 3-2A). These results indicated that RSV 
infection in neonates induced limited type I IFNs and pDC responses in the lung. 
 
 
IFN-α Treatment Prior to Neonatal RSV Infection Mitigated Airway 
Hyperreactivity and Lung Pathology during Reinfection 
 
Both our laboratory and other groups have shown that mice initially infected as 
neonates, compared to mice initially infected as adults, exhibit exacerbated airway 
hyperreactivity (AHR) and lung pathology during RSV reinfection (52-54); we therefore 
monitored lung function and pathology following reinfection in mice that were treated 
with IFN-α prior to neonatal RSV infection. Four-day-old pups were treated intranasally 
with 2 x 103 U [dose extrapolated from dosage used in adult mice (75)] of IFN-α or 
vehicle and then infected with RSV or serum-free media at 16 h post-treatment. These 
mice were then reinfected with RSV at 4 wks post-primary infection and AHR and lung 
pathology were assessed at 6 d post-reinfection (Figure 3-3). Pulmonary viral load data 
from other groups have shown that RSV infects and replicates in the lung following 
reinfection (53).  
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Figure 3-1. RSV infection induced limited type I IFNs in neonatal mouse lungs. 
Five-day-old neonates were infected with RSV and the expression of IFN-a4 was 
measured at various time points post-infection via real-time RT-PCR. N = 3-5 mice. To 
compare the protein levels of type I IFNs, neonates or adults were infected with RSV or 
media and the concentrations of IFN-α and IFN-β at 1 dpi were measured in lung 
homogenates using ELISA. (A) Kinetics of IFN-α in neonates. (B) IFN-α production in 
neonates and adults. (C) IFN-β production in neonates and adults. N = 3-4 mice. 
Individual data are shown with mean ± SEM, *p < 0.05. (This experiment was performed 
by Dahui) 
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Figure 3-2. RSV infection induced limited recruitment of pDCs to neonatal lungs. 
Five-day-old pups or adults were infected with RSV or sham and the numbers of pDCs in 
the lungs were measured using flow cytometry at various time points. (A) Kinetics of 
pulmonary pDCs expressed as percentages of total lung cells. (B) Kinetics of pDCs 
expressed as total numbers in lungs. (C) Representative flow plots for pDCs 
(CD11c+PDCA-1+) in neonates at 7 dpi. (D) Representative flow plots for pDCs in adults 
at 7 dpi. N = 4 mice, *p < 0.05 (RSV vs. sham), #p < 0.05 (adult vs. neonate). Data are 
presented as mean ± SEM.  
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Figure 3-3. IFN-α treatment prior to neonatal RSV infection attenuated AHR, 
inflammation, and mucus hyperproduction during RSV reinfection. 
Four-day-old pups were treated with IFN-α or vehicle. These mice were infected 16 h 
later, allowed to mature to adults, and reinfected with RSV at 4 weeks post-initial 
infection. Airway hyperactivity and lung pathology was assessed at six days post-
reinfection. (A) Airway resistance to methacholine. N = 5-6 mice, *p < 0.05.(B) Lung 
slides stained with H&E. Arrows indicate inflammatory cells. 100 x magnification. Scale 
bar = 200 µm. (C) Lung slides stained with PAS. Magenta staining indicates mucus. 
Arrows point to mucus-positive regions. 100x magnification. (D) Enlarged images of 
selected regions in C. 400x magnification. Scale bar = 50 µm. NS/sham: mice treated 
with vehicle and mock-infected; IFN-α/sham: mice treated with IFN-α and mock-
infected; NS/RR: mice treated with vehicle, infected as neonates, and reinfected with 
RSV as adults; IFN-α/RR: mice treated with IFN-α, infected as neonates, and reinfected 
with RSV as adults. Data are presented as mean ± SEM. (This experiment was performed 
by Dr. Dahui You in assistance with Dr. Jordy Saravia) 
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Expectedly, the airway resistance to methacholine in mice initially infected as 
neonates (NS/RR) was significantly higher compared to sham-infected mice (NS/Sham; 
6.44 ± 0.83 vs. 2.29 ± 0.38 cmH2O.s/mL) (Figure 3-3A). IFN-α treatment prior to 
neonatal RSV infection substantially decreased AHR (IFN-α/RR vs. NS/RR: 3.86 ± 0.81 
vs. 6.44 ± 0.83 cmH2O.s/mL), while there was no significant difference in AHR between 
mice treated with IFN-α prior to RSV infection with mice treated with vehicle prior to 
sham infection (IFN-α/RR vs. NS/Sham: 3.86 ± 0.81 vs. 2.29 ± 0.38 cmH2O.s/mL). No 
difference was observed in airway resistance between sham-infected mice treated with 
IFN-α and vehicle (NS/Sham vs. IFN-α/Sham: 2.50 ± 0.51 vs. 2.29 ± 0.38 cmH2O.s/mL). 
 
Consistent with the lung function data, lung pathology demonstrated that RSV 
reinfection induced moderate peribronchial and perivascular inflammation in the lung, 
which was reduced with IFN-α treatment prior to RSV infection (Figure 3-3B). In 
particular, a striking decrease in eosinophils was observed around the airways of mice 
treated with IFN-α compared to control mice (IFN-α/RR vs. NS/RR: 1,095 ± 185 vs. 66 ± 
31 eosinophils/surface area of lung parenchyma). In addition, significantly fewer mucus-
producing cells, indicated by positive PAS staining, were detected in the lungs of mice 
treated with IFN-α compared to control mice (Figure 3-3C&D); IFN-α/RR vs. NS/RR 
0.40 ± 0.02 vs. 0.26 ± 0.03 mucus+ cells/surface area of airway;). Little to no 
inflammation or mucus production was observed in mice treated with IFN-α or vehicle 
and sham-infected (data not shown). 
 
These data demonstrated a prophylactic effect of IFN-α on RSV infection in 
neonates that included significantly reduced AHR, pulmonary inflammation, and mucus 
hyperproduction during RSV reinfection. 
 
 
IFN-α Treatment Prior to Neonatal RSV Infection Mitigated Th2-biased Responses 
during Reinfection 
 
Cellular immunological analysis has previously revealed that the AHR and lung 
pathology in mice initially infected as neonates are associated with biased pulmonary Th2 
responses (52). We therefore measured various parameters of the Th cell immune 
response in the lung, including pulmonary Th cell subsets, cellularity of bronchoalveolar 
lavage fluid (BALF), and cytokine levels in BALF (Figure 3-4). 
 
Mice were treated and infected as above and lung cells were isolated at 6 d post-
reinfection and stained for surface markers, CD3 and CD4, and intracellular cytokines, 
IFN-γ and IL-4. We have previously shown that mice initially infected as neonates induce 
considerably more Th2 cells in the lung during reinfection compared to mice initially 
infected as adults, while the level of Th1 cells in the lung remain similar (hence Th2-
biased) (52). 
 
Here, we confirmed that RSV reinfection of mice initially infected as neonates 
(NS/RR) induced high levels of Th1 cells (CD3+CD4+IFN-γ+IL-4-) and moderate levels  
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Figure 3-4. IFN-α treatment prior to neonatal RSV infection mitigated the Th2-
biased responses during reinfection. 
Four-day-old pups were treated with IFN-α or vehicle. These mice were infected 16 h 
later, allowed to mature to adults, and reinfected with RSV at 4 wks post-initial infection. 
Pulmonary T helper cell profiles and BALF cellularity and cytokine levels were 
measured at 6 dpi. (A) Pulmonary Th profile. N = 4-5 mice. *p < 0.05. (B) 
Representative flow plot of Th cells from mice treated with IFN-α or vehicle and infected 
with RSV. (C) BALF cellularity. N = 5-6. *p < 0.05. (D) BALF cytokine levels. N=3-5 
mice. *p < 0.05. NS/sham: mice treated with vehicle and mock-infected; IFN-α/sham: 
mice treated with IFN-α and mock-infected; NS/RR: mice treated with vehicle, infected 
as neonates, and reinfected with RSV as adults; IFN-α/RR: mice treated with IFN-α, 
infected as neonates, and reinfected with RSV as adults. Data are presented as mean ± 
SEM. 
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of Th2 cells (CD3+CD4+IFN-γ-IL-4+) and multifunctional Th cells (CD3+CD4+IFN-γ+IL-
4+) in the lung (Figure 3-4A). IFN-α treatment prior to neonatal RSV infection 
substantially reduced the level of Th2 cells (IFN-α/RR vs. NS/RR: 0.84 ± 0.16 vs. 6.80 ± 
1.66%) and multifunctional cells (2.15 ± 0.42 vs. 9.39 ± 1.67%) while maintaining the 
level of Th1 cells (46.96 ± 2.14 vs. 42.94 ± 2.04%; Figure 3-4A-B). 
 
As in our previous publications (51, 52), RSV reinfection increased inflammatory 
cells in the BALF, including alveolar macrophages, lymphocytes, neutrophils, and 
eosinophils (Figure 3-4C). Consistent with reduced pulmonary inflammation (Figure 3-
4B), IFN-α treatment prior to neonatal RSV infection significantly decreased total 
inflammatory cells in the BALF during reinfection compared to mice treated with vehicle 
(IFN-α/RR vs. NS/RR: 2.96 ± 0.34 vs. 6.04 ± 0.96 x 105 cells/mL). This decrease in total 
inflammatory cells was mainly due to the decrease in eosinophils (0.20 ± 0.07 vs. 1.92 ± 
0.32 x 105 cells/mL). 
 
In line with the BALF cellularity and pulmonary Th profile, IFN-α treatment prior 
to neonatal RSV infection significantly reduced Th2 cytokines in BALF during 
reinfection, including both IL-4 and IL-13 (Figure 3-4D; IFN-α/RR vs. NS/RR: 0.98 ± 
0.12 vs. 9.88 ± 1.42 and 34.10 ± 9.47 vs. 137.93 ± 15.1 pg/mL). No difference in Th1 
cytokines was observed between IFN-α- and vehicle-treated mice, including both IFN-γ 
and IL-12 (82.79 ± 19.31 vs. 74.70 ± 22.76 and 40.98 ± 9.53 vs. 37.00 ± 9.12 pg/mL). 
Collectively, the pulmonary Th profile, BALF cellularity and cytokine levels shown 
above demonstrated that IFN-α treatment prior to neonatal RSV infection decreased Th2-
biased responses and reduced RSV pathogenesis upon reinfection. 
 
 
Adoptive Transfer of Purified Adult pDCs Prior to Neonatal RSV Infection Induced 
Pulmonary IFN-α Expression and Alleviated RSV Reinfection-Associated 
Immunopathophysiology 
 
As demonstrated above, RSV infection induced limited pDC and type I IFN 
responses in the neonatal lung. Additionally, IFN-α treatment prior to neonatal RSV 
infection reduced the typical Th2 immunopathophysiology during reinfection. Because 
pDCs are the major source of type I IFNs (111), we hypothesized that adoptive transfer 
adult pDCs prior to neonatal RSV infection would also reduce the Th2 
immunopathophysiology during reinfection. Four-day-old pups received 3 x 104 adult 
pDCs instilled intranasally. The number of pDCs instilled was roughly the number of 
pulmonary pDCs observed in adult naïve mice. Because it is extraordinarily difficult to 
isolate this number of pDCs from neonates, control pups received vehicle (serum-free 
medium; SFM). Pups were infected with RSV at 16 h post-adoptive transfer and re-
infected at 4 weeks post-initial infection. Various endpoints were measured at 6 d post-
reinfection, including AHR, BALF cellularity, and pulmonary Th profile (Figure 3-5). A 
set of pups was used to measure the IFN-α expression in the lung at 1 dpi. 
 
Because pDCs are the major source of type I IFNs during viral infections, we 
measured the expression of IFN-α in lung homogenates at 1 dpi in pups receiving adult  
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Figure 3-5. Adoptive transfer of adult pDCs prior to neonatal RSV infection 
induced pulmonary IFN-α expression and attenuated the Th2-biased 
immunopathologies during RSV reinfection. 
Four-day-old pups received adult pDCs (A-E) or CD11c+ cells (F) or serum-free medium 
(SFM, A-F) 16 h before initial RSV infection. After four weeks, these mice were 
reinfected with RSV, and airway resistance, BALF cellularity, and Th cell profiles were 
measured at six days post-reinfection. (A) Relative IFNα expression in the lung 
homogenates at 1 dpi. N = 5 mice. *p < 0.05. (B) Airway resistance to methacholine. N = 
4-5 mice, *p < 0.05. (C) BALF cellularity. N = 4-5, *p < 0.05. (D) Pulmonary Th profile. 
N = 4-6 mice, *p < 0.05. (E) Representative flow plot of D. (F) Pulmonary Th profile in 
mice receiving CD11c+ cells or SFM. N = 5 mice, *p < 0.05. SFM/RSV: pups receiving 
SFM and infected with RSV; pDC/RSV: pups receiving adult pDCs and infected with 
RSV; SFM/sham: mice receiving SFM and mock-infected; pDC/sham: mice receiving 
pDCs and mock-infected; SFM/RR: mice receiving SFM, infected as neonates, and 
reinfected with RSV as adults; pDC/RR: mice receiving pDCs, infected as neonates, and 
reinfected with RSV as adults. CD11c+/RR: mice receiving CD11c+ cells, infected as 
neonates, and reinfected with RSV as adults. Data are presented as mean ± SEM. 
( Dr. Dahui You performed parts of these experiments.) 
  
 45 
pDCs or vehicle. As shown in (Figure 3-5A), pups receiving adult pDCs exhibited a six-
fold induction of IFN-α in the lungs compared to the mice receiving vehicle. 
 
RSV reinfection induced AHR in mice initially infected as neonates compared to 
sham-infected mice (Figure 3-5B; SFM/RR vs. SFM/Sham: 6.60 ± 1.01 vs. 1.62 ± 0.15 
cmH2O.s/mL). Adoptive transfer of adult pDCs to the lung prior to neonatal RSV 
infection significantly reduced AHR compared to control mice (pDC/RR vs. SFM/RR: 
4.80 ± 1.03 vs. 6.60 ± 1.01 cmH2O.s/mL); and the airway resistance in mice receiving 
adult pDCs was no different than mice receiving vehicle and sham-infected (pDC/Sham 
vs. SFM/Sham: 1.45 ± 0.14 vs. 1.62 ± 0.15 cmH2O.s/mL). 
 
Analysis of BALF cellularity demonstrated significant reductions in the number 
of alveolar macrophages (0.56 ± 0.09 vs. 0.97 ± 0.09 x 105 cells/mL), neutrophils (0.51 ± 
0.18 vs. 1.14 ± 0.22 cells/mL), and particularly eosinophils (0.07 ± 0.03 vs. 0.43 ± 0.16 
cells/mL) during reinfection in the airways of mice receiving adult pDCs and infected 
with RSV as neonates (pDC/RR) compared to control mice receiving vehicle (SFM/RR) 
(Figure 3-5C). The total inflammatory cells and lymphocytes remained comparable 
between pDC/RR and SFM/RR mice. In addition, mice receiving adult pDCs prior to 
neonatal RSV infection (pDC/RR) recruited fewer Th2 (1.31 ± 0.22 vs. 3.50 ± 0.69%) 
and multifunctional Th cells (5.05 ± 0.33 vs. 9.54 ± 2.13%) and more Th1 cells (57.78 ± 
2.11 vs. 49.02 ± 1.59%) compared to mice receiving vehicle (SFM/RR; Figure 3-5 
D&E). 
 
In order to exclude the possibility that the effects we observed were due to the 
adoptive transfer of any type of cells into the neonatal lung, the above experiment was 
repeated with 3 x 104 CD11c+ cells purified from adult spleens and the Th cell profile 
during reinfection was analyzed. As shown in (Figure 3-5F), no difference was observed 
in any Th cell subset between the mice receiving vehicle or CD11c+ cells. 
 
Collectively, these data showed that adoptive transfer of purified pDCs into the 
lungs prior to neonatal RSV infection decreased AHR, airway inflammation and 
eosinophilia, and pulmonary Th2-biased immune responses during RSV reinfection. 
 
 
IFN-α Treatment or Adoptive Transfer of pDCs Prior to Neonatal RSV Infection 
Reduced Pulmonary Viral Load during Primary Infection 
 
Both IFN-α treatment and adoptive transfer of adult pDCs prior to neonatal RSV 
infection decreased Th2-associated immunohistopathology during reinfection. Because 
IFN-α is an important anti-viral cytokine and is produced mainly by pDCs (111), we 
hypothesized that IFN-α treatment or adoptive transfer of pDCs prior to RSV infection 
reduces pulmonary viral load. Four-day-old pups were intranasally instilled with 2 x 103 
U of IFN-α or 3 x 104 pDCs or vehicle. Sixteen hours after instillation, these mice were 
infected with RSV and lungs were isolated at 4 dpi for virus quantification using both 
plaque assays and real-time RT-PCR (Figure 3-6). 
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Figure 3-6. IFN-α treatment or adoptive transfer of pDCs decreased pulmonary 
viral load during primary RSV infection.  
Four-day-old pups were treated with IFN-α or vehicle or received pDCs at 16 h prior to 
RSV infection. At 4 dpi, lungs were isolated and viral loads were measured in lung 
homogenates by plaque assay or real time RT-PCR. (A) Plaque assay. N = 12-15 mice, 
*p < 0.05. (B) Relative expression of NS1. Ct values were normalized to Hprt (house-
keeping gene) and then compared to NS/RSV mice. N = 4-5 mice, *p < 0.05. NS/RSV: 
mice treated with vehicle and infected with RSV; IFN-α/RSV: mice treated with IFN-α 
and infected with RSV; pDC/RSV: mice receiving pDCs and infected with RSV. 
Individual data are shown with mean ± SEM. (Dr. Dahui You performed this experiment) 
  
 47 
Plaque assays demonstrated that IFN-α treatment considerably reduced live RSV 
titer from 280 ± 43 to 91 ± 15 PFU/g of lung (Figure 3-6A). Consistent with the plaque 
assay data, real-time RT-PCR data demonstrated a 96% reduction in relative expression 
of the NS1 gene in mice pre-treated with IFN-α compared to control mice receiving 
vehicle (Figure 3-6B). The adoptive transfer of pDCs prior to RSV infection similarly 
resulted in a moderate, but significant, reduction in pulmonary viral load, as evidenced by 
decreased live RSV titer from 280 ± 43 to 172 ± 28 PFU/g of lung and a 66% reduction 
in relative expression of NS1 gene compared to mice receiving vehicle. 
 
 
IFN-α Treatment Prior to Neonatal RSV Infection Reduced IL-4Rα Expression on 
T Helper Cells during Primary Infection 
 
As mentioned above, we and other groups have shown that the hallmark of the 
immunopathophysiology during reinfection in mice initially infected as neonates are the 
biased Th2 responses following reinfection in the adult. Because IFN-α treatment prior to 
neonatal RSV infection reduced these Th2-biased responses to RSV upon reinfection 
(86), we sought to determine if IFN-α treatment also changed the Th profile in the lung 
during primary infection (Figure 3-7). Four-day-old pups were instilled with IFN-α prior 
to RSV infection. The Th profile was measured in the lung at 6 dpi using flow cytometry. 
 
Neonatal RSV infection induced the recruitment of Th1 cells, Th2 cells, and 
multifunctional Th cells in the lungs (Figure 3-7A&B). Treatment with IFN-α prior to 
RSV infection reduced all of these Th subsets. Th1 cells declined from 0.49 ± 0.05 to 
0.34 ±0.032%, Th2 cells decreased from 0.057 ±0.006 to 0.027 ± 0.005%, and 
multifunctional Th cells decreased from 0.006 ± 0.001 to 0.001 ± 0.0003% of CD4+ T 
cells. In fact, the levels of these 3 Th subsets decreased to homeostatic baseline levels, as 
observed in the sham-infected mice (NS/Sham or IFN-α/Sham), despite the fact that live 
virus was detected in the lungs of IFN-α-treated and RSV-infected mice (Figure 3-6). 
 
Importantly, we have recently shown that IL-4Rα expression on Th cells plays a 
central pathogenic role in the Th2-biased responses of mice initially infected as neonates 
(51); we therefore measured the level of IL-4Rα on Th cells during initial RSV infection. 
Mice were treated with IFN-α prior to RSV infection and IL-4Rα levels on pulmonary 
CD4+ T cells were measured at 2 dpi, as previously published (52). Consistent with our 
previous findings (52), RSV infection in neonates did not change the expression of IL-
4Rα on CD4+ T, Th1, and Th2 cells (Figure 3-7C-E). Treatment with IFN-α significantly 
reduced the expression of IL-4Rα on Th2 cells. There was no significant decrease in 
expression of IL-4Rα on Th1 cells observed between IFN-α and vehicle-treated mice 
(IFN-α/RSV vs. NS/RSV) or between IFN-α treated, RSV-infected mice (IFN-α/RSV) 
and sham-infected mice (NS/Sham or IFN-α/Sham). 
 
Collectively, the data shown above demonstrated that IFN-α treatment prior to 
neonatal RSV infection reduced pulmonary Th cell responses and IL-4Rα expression on 
Th2 cells while decreasing viral load, suggesting dual mechanisms of action. 
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Figure 3-7. IFN-α treatment reduced Th responses to primary RSV infection in 
neonates. 
Four-day-old pups were treated with IFN-α or vehicle at 16 h prior to RSV infection. 
Pulmonary T cell profile or IL-4Rα expression on Th cells was measured at 6 dpi or 2 
dpi, respectively. (A) Pulmonary Th profile at 6 dpi. N = 5-8 mice, *p < 0.05. Data are 
presented as mean ± SEM. (B) Representative flow plots of the Th profile. (C) Relative 
expression of IL-4Rα on CD4+ T cells. (D) Relative expression of IL-4Rα expression on 
Th1 cells. (E) Relative expression of IL-4Rα on Th2 cells. N = 9-12 mice, *p < 0.05. 
NS/Sham: mice treated with vehicle and mock-infected; IFN-α/Sham: mice treated with 
IFN-α and mock-infected; NS/RSV: mice treated with vehicle and infected with RSV; 
IFN-α/RSV: mice treated with IFN-α and infected with RSV. Individual data are shown 
with mean ± SEM.  
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Discussion 
 
Despite nearly 60 years of intense research on RSV, we still have no efficacious 
vaccines or therapeutics for this virus. The initial use of adult instead of neonatal animal 
models and the lack of knowledge of immune responses in infants are partially 
responsible for the slow progress. In fact, mice infected initially as neonates develop 
biased Th2 pulmonary immune responses upon reinfection with RSV; whereas mice 
initially infected as adults develop dominant Th1 responses upon reinfection with RSV. 
In the present study, we investigated the role of pDCs and type I IFNs in the pathogenesis 
of RSV using our neonatal mouse model. We showed that primary RSV infection in 
neonatal mice induced limited pDC and type I IFN responses compared to adult mice. 
We further demonstrated that intranasal instillation of recombinant IFN-α or the adoptive 
transfer of adult pDCs to the lungs prior to neonatal RSV infection considerably 
decreased immunopathophysiology during RSV reinfection, including reducing AHR, 
eosinophilia, mucus hyperproduction, and pulmonary Th2 responses. These data suggest 
that the limited pDC responses and type I IFN responses in neonates during primary 
infection permit the Th2-biased immunopathogenesis during RSV reinfection. 
 
Although both prophylactic IFN-α and adoptive transfer of adult pDCs exerted 
similar immunomodulatory effects during RSV reinfection, there are differences in the 
extent of the effects between the two treatments that cannot be explained by the 
differences in the anti-viral properties of IFN-α and pDCs (i.e., pDC transfer had less of 
an effect on viral load than IFN-α treatment). These differences include: 1) IFN-α 
treatment decreased the number of eosinophils and had no effect on other cell types in the 
BALF during reinfection; whereas adoptive transfer of pDCs decreased eosinophils, 
monocytes, and neutrophils (Figure 3-4C vs. 3-5B) IFN-α treatment decreased 
pulmonary Th2 cells but had no effect on Th1 cells during reinfection; whereas adoptive 
transfer of pDCs decreased Th2 cells and increased Th1 cells in the lung (Figure 3-4A 
vs. 3-5C). Although not tested in, and outside of the scope of, this study, these 
differences might be due to properties other than the anti-viral effect of pDCs. For 
example, in addition to producing IFN-α upon viral infection, pDCs have been shown to 
acquire dendrites, upregulate MHCII and co-stimulatory molecules, and activate naïve T 
cells (112). Therefore, adoptively transferred adult pDCs might serve not only as a source 
of IFN-α but also as additional antigen presentation cells driving the immune response 
towards the Th1 arm. Interestingly, adoptive transfer of adult pDCs prior to RSV 
infection in the neonate appeared to be less protective during the initial infection (i.e., 
higher pulmonary viral load) and less beneficial during reinfection (i.e., increased AHR) 
than administration of IFN-α. This phenomenon may be because the number of 
transferred pDCs was insufficient to overcome the neonatal immune microenvironment 
of the lung. 
 
The mechanisms via which IFN-α treatment mitigated the Th2-biased 
immunopathologies during RSV reinfection in mice initially infected as neonates appear 
to be multifactorial. The reduction in viral load (86) undoubtedly accounts for some 
improvement in RSV mediated disease. Although it is difficult to dissociate the anti-viral 
effects of IFN-α, our previous publication clearly demonstrated that enhanced IL-4Rα 
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expression on neonatal Th cells compared to adult Th cells plays a significant role in the 
development of the Th2 biased immunopathologies following RSV reinfection (52). 
Furthermore, reduction of IL-4Rα on Th2 cells during primary infection prevents Th2 
bias, airway hyperreactivity, mucus hyperproduction, and inflammation upon reinfection 
without affecting viral load (38). In line with this observation, the data presented here 
demonstrate that IFN-α treatment prior to RSV infection reduces the expression of IL-
4Rα on Th2 cells (Figure 3-7E). Because IL-4Rα levels are higher in neonates, where 
viral loads are lower compared to adults (55) and do not change in response to RSV 
infection (52), we also propose that the immunomodulatory aspects of IFN-α play a role 
in the effects observed here. Thus, we believe that both of the mechanisms of IFN-α 
action outlined above are involved in the observed protective effect. 
 
Although IFN-α-induced downregulation of IL-4Rα was moderate during primary 
infection, the outcome of disease following reinfection was substantial (i.e., airway 
function is improved and pulmonary inflammation, mucus hyperproduction, and the Th2-
biased response was dramatically reduced). In fact, these results were strikingly similar to 
what we have previously published with antisense oligonucleotides to IL-4Rα- moderate 
downregulation of IL-4Rα during neonatal RSV infection completely abolished 
reinfection-associated airway hyperactivity and significantly decreased Th2-biased 
responses. We believe this phenomenon to be due to fine-tuning of IL-4Rα signaling, 
which results in a rebalancing of the immune response so that Th2 cells no longer skew 
the immune response. This is evidenced by the primary Th response in which the ratio of 
Th1/Th2 is increased in IFN-α treated mice (IFN-α/RSV vs. NS/RSV: 9.230 ± 8.230 vs. 
5.137 ± 4.137). 
 
In addition to its antiviral effects, IFN-α has also been shown to promote Th1 
responses (113) and suppress Th2 responses (114) ex vivo. As expected in our model 
(Figure 3-7A) IFN-α treatment prior to neonatal RSV infection significantly decreased 
pulmonary Th2 cells. Surprisingly, pulmonary Th1 cells were reduced in IFN-α-treated 
neonates following RSV infection. Most importantly, the Th cell responses to RSV in 
IFN-α treated neonatal mice were reduced to the same level as those in sham-infected 
animals. The reason for the decrease in pulmonary Th1 cells following RSV infection in 
the neonate treated with IFN-α is unclear (Figure 3-7A). We cannot exclude the 
possibility that the reduction in pulmonary viral load is responsible for the decrease in 
pulmonary Th1 cells in IFN-α-treated, RSV infected neonates, but our data presented 
here demonstrating that IFN-α modulates IL-4Rα levels during initial infection and our 
prior data demonstrating that modulating IL-4Rα levels at time of initial infection in the 
neonate suggest that IFN-α also modulates Th1/Th2 balance. Thus, we believe our data 
support two mechanisms of IFN-α activity on reducing RSV-mediated disease: 1) it 
reduces viral load and 2) it modulates immune responses through IL-4Rα. We feel that 
our data are instructive for RSV vaccine design and suggest that an adjuvant capable of 
inducing IFN-α responses offers additional benefit due to its ability to modulate the 
neonatal immune response. 
 
There were early attempts in late 80s and early 90s to test the feasibility of IFN-α 
as an RSV therapeutic. Unfortunately, the clinical trial showed that daily intramuscular 
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injection of IFN-α into RSV-infected infants for three consecutive days did not change 
the overall clinical course, duration of oxygen requirement, or viral shedding; although 
the treatment did induce a more rapid drop of clinical score during the first three days 
(115). The difference between these human studies and our data in neonates may be 
explained by the different strategies we employed. First, in our model, IFN-α was 
instilled directly onto the mucosal surface where RSV infection naturally occurs, whereas 
in the human studies IFN-α was administered systemically. Second, in our model, IFN-α 
was instilled prior to RSV infection in the hope of preventing Th2-biased responses 
during reinfection, whereas in the human studies IFN-α was administered after RSV 
infection as a therapy. One very important result of this human study is that it 
demonstrated that the usage of IFN-α in infants is safe (116). In fact, RSV-infected 
infants ranging from two to eight months old received daily maximal 70,000 U of IFN-α 
per kg of body weight with no toxicity observed. One of the most intimidating difficulties 
in RSV vaccine or therapeutic research is that RSV is an infant disease and any 
intervention for infants has to be applied with considerable forethought and extreme 
caution. We feel that the safety of IFN-α in human infants and the encouraging results 
from our studies strongly suggests that IFN-α is a promising target for future RSV 
vaccine design due to its immunomodulatory property. 
 
In summary, limited type I IFN and pDC responses in neonatal mice permit the 
development of Th2-biased immunopathogenesis during RSV reinfection. IFN-α or 
adoptive transfer of adult pDCs prior to neonatal RSV infection reduced the Th2-biased 
immunopathophysiologies, possibly because of their antiviral properties and by 
downregulating IL-4Rα expression on Th2 cells. These observations support using an 
adjuvant capable of inducing IFN-α in future RSV vaccine strategies.  
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CHAPTER 4.    DISCUSSION, CONCLUSION, AND PERSPECTIVE 
 
 
A Role for IL-4Rα on mDCs in RSV Infection 
 
Our lab and others have demonstrated that RSV infection of neonates leads to Th2 
biased responses, which are partly responsible for RSV pathology (52-54). Further, we 
have shown that downregulation of IL-4Rα in the lung using ASO is protective against 
Th2-biased immunopathogenesis in neonatal mice induced by RSV (51). A significant 
decrease in IL-4Rα levels on mDCs was observed in concurrence with remediation of 
RSV disease (51). In chapter 2, we observed elevated levels of IL-4Rα on pulmonary 
CD11b+ mDCs in neonates compared to that of adults. Deletion of IL-4Rα on neonatal 
CD11c+ cells (which included CD11b+ mDCs) resulted in a significant reduction in Th2 
biased responses (Th2 cells, cytokines, and eosinophils), airway hyperreactivity, and 
inflammation following RSV reinfection. An increase in Th1 promoting cytokine (IL-12) 
was seen along with the decrease in Th2 biased responses. The specific role of IL-4Rα on 
neonatal CD11b+ mDCs in Th2 induction in response to RSV was demonstrated via in 
vitro T cell activation assay. Conversely, overexpressing IL-4Rα on adult CD11b+ mDCs 
and adoptive transfer of these cells into adult lungs prior to RSV infection resulted in Th2 
biased responses to RSV similar to what is observed with neonatal RSV infection. 
 
This body of work added the novel finding that differences in IL-4Rα levels exist 
between mDCs at different ages. How exactly IL-4Rα expression on mDCs changes with 
age remains to be understood. Our data suggest that elevated IL-4Rα levels, as occurs on 
neonatal mDCs, inhibits the ability of these mDCs to mature and a decreased ability to 
produce IL-12 in response to RSV infection. Surprisingly, IL-4 treatment on BMDCs has 
been shown to promote IL-12 production and DCs maturation (89, 117). This dichotomy 
could be explained by the distinct roles of two types of IL-4R. While IL-4 signaling 
through type I IL-4R on mDCs promotes IL-12 production, IL-13 signaling through type 
II IL-4R has been shown to suppress it (118). Our data support the latter result because 
we observed high levels of IL-13, but not IL-4, and low levels of IL-12 in mice after RSV 
infection (119). 
 
Our data from human infants hospitalized with RSV suggest another possible 
mechanism. In these data, we observed elevated IL-13 levels in nasal aspirates of 
children hospitalized with RSV (119). IL-13 levels positively correlated with IL-33 levels 
in the infants (119). IL-33 has been shown to act on mDCs and increase OX-40L 
expression (120). OX-40L further promotes Th2 biased responses (121) to RSV. 
 
 
pDC and IFN-α in Neonatal RSV Infection 
 
In chapter 3, we discovered differences in recruitment of pDCs in lungs of 
neonates versus adults in RSV infection. There were significantly less pulmonary pDCs 
and type I IFNs in neonates upon RSV infection compared to that of adults. This 
correlates with human data where lower amounts of type I IFNs are observed in infants 
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infected with RSV (76). Treatment with recombinant type I IFN-α or adoptive transfer of 
adult pDCs into neonatal mice prior to neonatal RSV infection prevented RSV induced 
Th2 biased immunopathophysiology including pulmonary Th2 responses, eosinophilia, 
AHR, and mucus hyperproduction even after reinfection. Mechanistically, we determined 
that treatment with type I IFN- α significantly reduced RSV viral load in the lungs of 
mice and downregulated the levels of IL-4Rα levels on Th2 cells. 
 
In chapter 1, we observed also differences in IL-4Rα expression on pDCs in 
neonates compared to that of adults. We speculate that high levels of IL-4Rα on pDCs are 
responsible for a reduced type I IFN response in neonates in RSV infection. This 
speculation is supported by a study where IL-4 or IL-13 treatment on pDCs that signals 
through IL-4Rα reduced type I IFN-α production (122). How exactly IL-4Rα levels affect 
type I IFNs production from pDCs is yet to be studied. Presumably, higher levels of IL-
4Rα signaling inhibit the IFN-α receptor (IFNAR) signaling that promotes type I IFN 
responses in pDCs. 
 
 
Concluding Remarks 
 
RSV causes significant health consequences in infant and elderly populations. 
Here we focused on the pulmonary immunopathology that develops in association with 
RSV infection in infants. Age at time of RSV infection remains a critical factor because 
infants who are infected are more likely to develop chronic respiratory diseases like 
asthma. Although epidemiological data have shown a connection between RSV infection 
and the development of asthma later in life, there is little in the literature establishing 
mechanisms for this process. The link between RSV infection during infancy and 
development of respiratory disease continues to be an area of investigation. 
 
We and others have shown that mouse neonates and human infants respond with 
Th2 biased responses to RSV (43, 52, 123). Our group has determined some mechanistic 
explanations for the Th2 biased responses to RSV (Figure 4-1) but more questions need 
to be addressed. Using an IL-4Rα ASO prior to RSV infection (51), we were able to 
protect neonatal mice from RSV immunopathophysiology. Downregulation of IL-4Rα in 
these studies occurred on CD4+ T cells, mDCs, and airway epithelial cells. Recently, we 
discovered high levels of IL-33 in neonatal mice and human infants with severe RSV 
infection (119), presumably from epithelial cells. So, I hypothesize that high levels of IL-
4Rα on epithelial cells promote IL-33 in neonatal mice in RSV infection. Further, IL-33 
has been shown to activate OX-40L on mDCs which play an important role in Th2 biased 
responses (121). IL-33 also activates ILC2s to release high amounts of IL-13 in response 
to RSV (119, 124). Here, chapter 2 and chapter 3 demonstrated the role of IL-13:IL-4Rα 
signaling in suppressing production of IL-12 and IFN-α cytokines from DCs in RSV 
infection. This suppression of Th1 promoting cytokines leads to Th2 biased responses 
following RSV infection in neonatal mice. Elevations of IL-13 and decreased IFN-α in 
nasal secretions from infants with severe RSV disease suggest that this is also occurring 
in humans. 
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Figure 4-1. Schematic representation of immune response to RSV in neonates. 
RSV infection of neonatal epithelial cells releases IL-33, which activates ILC2s to 
produce IL-13 (122). The Th2 cytokine, IL-13 binds to IL-4Rα on DCs allowing 
suppression of IL-12 and IFN-α production or binds to epithelial cells which result in 
production of more IL-33. IL-33 can also bind to OX-40L on mDCs controlling their 
ability to mature in response to RSV. Low levels of Th1 promoting cytokines IFN-α and 
IL-12 lead to Th2 biased responses (128, 129) in neonates following RSV infection. Blue 
arrow head denotes my own findings in this dissertation. Black arrow head represents 
relationships discovered by others (122). Dashed line represents unknown.  
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Overall, our studies have highlighted the differences in neonatal and adult 
immunity to RSV including different mechanisms that are responsible for the induction 
of the Th2 responses in neonates. Understanding differences between neonatal and adult 
immunity can lead towards the development of novel therapeutics to prevent RSV 
induced immunopathophysiology and inform vaccine strategies. 
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